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Summary 
Gonadotropin-releasing hormone (GnRH) is the first key hormone of reproduction. The 
binding of GnRH to its cognate type I receptor initiates diverse signaling cascades. 
Among them, the GnRH-induced MAPK cascades are the most studied and characterized, 
which are proved to facilitate the transcriptional regulation of gonadotropins. Besides 
MAPK signaling cascades, however, recent studies indicate that GnRH-induced 
gonadotropin production may also be regulated through other signaling pathways. In 
addition, the regulation of gonadotropins is implicated to not only occur at the 
transcriptional level but also at the post-transcriptional, translational and posttranslational 
levels. Moreover, the gonadotropins are found to be differentially regulated by GnRH 
pulse frequency. However, the mechanisms by which gonadotropins decipher the GnRH 
pulse frequency are yet to be clear. We performed cICAT proteomic profiling to compare 
the whole cell lysate from mock-treated and GnRH-treated LβT2 cells, and identified a 
number of promising factors involved in mediating GnRH response through Wnt 
signaling.  Furthermore we did different GnRH frequency treatments in LβT2 cells, and 
performed iTRAQ-based proteomic experiment to compare nuclear cell lysate from 
mock-treated and GnRH-treated LβT2 cells. Gene ontology study identified the top-
ranked biological processes, in which the identified proteins are involved. Among these, 
certain numbers of regulated proteins are found to be involved in mRNA processing, 
translation and chromosome organization, which are closely correlated to 
posttranscriptional, translational and posttranslational regulations, suggesting the novel 
regulatory roles of GnRH other than transcriptional regulation. Besides, the functions of 
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these regulated proteins as well as the percentile of the regulated proteins fell in each 
function category were found to be differentially distributed in different GnRH frequency 
treatment group, suggesting that the functions of these proteins are correlated with 
underlying GnRH decoding mechanism. Furthermore, ACTN4 was identified as a 
negative regulator of FSHβ subunit-gene transcription and its C-terminal Cam-like 
domain was required for the regulation. Our findings suggested that GnRH-induced 
ACTN4 nuclear translocation may facilitate the transcriptional activation of FSHβ 
subunit-gene, possibly through mediating the crosstalk of Ca
2+ 
signaling with the MAPK 
pathways. This study provided valuable clues and suggestions for the future researchers 
to explore the underlying GnRH-induced regulatory mechanism, as well as potential drug 
targets for the therapy of reproductive aberrancy and deficiency related diseases.  
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1.1 Gonadotropins and Gonadotropin-Releasing Hormone 
1.1.1 Physiology of the gonadotropins 
Reproduction plays critically important roles in sustentions and evolution of any animal's 
life. In all vertebrates, reproduction is controlled by the brain through the highly 
conserved hypothalamic-pituitary-gonadal (HPG) axis (Figure 1.1). Gonadotropin 
releasing hormone (GnRH) neurons, which are located in the hypothalamic-preoptic area 
of the brain, ultimately control reproduction by incorporating internal information such as 
nutritional and hormonal state with those social and environmental signals. This 
integration results in the production and release of GnRH to the pituitary gland. GnRH is 
highly conserved across all vertebrates and is the pivotal regulator of gonadotopins. It 
was recently also found in several invertebrates, emphasizing its evolutionary importance 
(Tsai 2006).  
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Figure 1.1 Schematic representation of the hypothalamic-pituitary-gonadal axis. 
(A) The pituitary gland is a small, bean-sized organ, which is beneath the brain in a well-
protected position. (B) GnRH is secreted from the hypothalamus. After binding with the 
GnRH receptors on the surface of the anterior pituitary gonadotrope, it acts on the gonads 
to stimulate the synthesis and secretion of LH and FSH (Brown and McNeilly 1999).  
 
1.1.2 Subunits of gonadotropins 
The gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH) 
belong to the glycoprotein hormone family, which also includes thyroid stimulating 
hormone (TSH) and chronic gonadotropins (CG) (Pierce and Parsons 1981). LH and FSH 
are heterodimeric hormones sharing a common α-subunit, while owning a hormone 
specific β-subunit (Figure 1.2). The β-subunit specifies the biological activity and 
physiological particularity of each gonadotropin (Gharib, Wierman et al. 1990). The 
common α and specific β-subunits are localized on different chromosomes. The 
coordinated transcription and non-covalent assembly of these two subunits control the 
synthesis of biologically active LH and FSH. 
 
Figure 1.2 Schematic demonstration of subunits of gonadotropins.  
Each of LH and FSH has a common α-subunit (orange), and a hormone-specific β-
subunit (Gharib, Wierman et al. 1990).  
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1.1.3 Biological functions of the gonadotropins  
LH and FSH initiate sexual maturation and maintain cyclical reproductive function upon 
binding to their specific receptors in the gonad (Figure 1.3). In the testis, LH acts on the 
Leydig cells to stimulate synthesis and secretion of steroid hormones, especially the 
production of androgens (Dufau 1988), while FSH targets the Sertoli cells to stimulate 
production of sperms (Tapanainen, Aittomaki et al. 1997). In the ovary, FSH stimulates 
maturation of ovarian follicles and conversion of androgens to estrogens (Aittomäki, 
Herva et al. 1996; Kumar, Wang et al. 1997), while LH promotes maturation of follicular 
cells. After the initial LH receptor (LHR) expression in the small follicles, LH enhances 
the subsequent stages of follicular development in granulosa and luteal cells (Richards 
and Hedin 1988). The preovulatory LH surge triggers ovulation of mature follicles by 
promoting the rupture of the follicle and the release of the ovum. In addition, LH also 
leads to the synthesis and subsequent release of progesterone by the corpus luteum 
(Norris 1997).   
24 
 
Figure 1.3 Schematic demonstration of biological functions of gonadotropins. 
LH and FSH produce steroid hormones: testosterone, estrogen and progesterone in 
gonads, which in turn positively or negatively regulate the synthesis of gonadotropins 
(Brown and McNeilly 1999).  
 
1.1.4 Therapeutic applications of GnRH 
GnRH agonist (GnRHa) analogs, peptides mimic the function of GnRH, have been used 
to treat steroid-dependent diseases (Schultze-Mosgau, Griesinger et al. 2005) and proved 
to be a safe and efficient class of drugs. The existing treatments using GnRHa medication 
include precocious puberty, endometriosis, fibroids, breast cancer, and prostate cancer 
(Beyer, Amari et al. 2011). Typical side effects caused by estrogen withdrawal are 
acceptable for cancer treatment, and can be effectively reliefed  through “add back” 
therapy, which utilizes combination of low dose estrogen and progesterone (Moghissi, 
Schlaff et al. 1998; Schlaff 1999).  
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1.2 Molecular regulation of gonadotropin synthesis and secretion 
The synthesis and secretion of gonadotropins LH and FSH are regulated by a series of 
factors along the hypothalamus-pituitary-gonad axis, including gonadotropin-releasing 
hormone (GnRH), steroid hormones (estrogen, androgen and progesterone) and gonadal 
peptides (activin and inhibin) (Landefeld, Kepa et al. 1983; Ling, Ying et al. 1986; 
Papavasiliou, Zmeili et al. 1986; Gharib, Wierman et al. 1990). GnRH is the main 
regulator of gonadotropins. It is secreted from hypothalamus and delivered to the 
gonadotrope in pulses of different frequency and amplitude (Haisenleder, Katt et al. 1988; 
Dalkin, Haisenleder et al. 1989; Haisenleder, Dalkin et al. 1991; Kirk, Dalkin et al. 1994). 
This pulsatile secretion of GnRH results in the differential regulation of the expression of 
LHβ and FSHβ. Gonadal steroids and peptides act either on the hypothalamus to alter 
GnRH pulsatility or on the pituitary to regulate LH and FSH synthesis and secretion 
(Landefeld, Kepa et al. 1984; Dalkin, Paul et al. 1992; Roy, Angelini et al. 1999). Current 
knowledge about GnRH-induced regulation of gonadotropin genes are mainly in two 
aspects: one is the factors involved in the regulation of basal transcriptional machinery, 
which include cis-elements and transcription factors mediating the GnRH signaling to the 
LHβ and FSHβ promoters, the other is GnRH-induced signaling pathways. 
1.2.1 Basal level regulation of gonadotropins 
1.2.1.1 Transcriptional machinery on the LHβ promoter 
The mammalian LHβ promoter contains two regions: the proximal and distal regions. 
The proximal 140 bp region is highly conserved across all species. It contains Pituitary 
homeobox 1 (Pitx-1), Steroidogenic factor 1 (Sf-1) and Early growth factor 1 (Egr-1) 
binding sites, which act functionally and synergistically to mediate the basal and GnRH-
26 
stimulated LHβ promoter activity, by recruiting other coactivators to the promoter 
(Halvorson, Ito et al. 1998; Dorn, Ou et al. 1999; Tremblay and Drouin 1999; Quirk, 
Lozada et al. 2001). Sf-1 is an orphan nuclear receptor found  in the gonadotropes of the 
anterior pituitary and also in other non-pituitary steroidogenic tissues including the 
adrenal glands, gonads, and placenta and the ventromedial nucleus of the hypothalamus 
(Ikeda, Lala et al. 1993; Luo, Ikeda et al. 1994; Ikeda, Luo et al. 1995). Sf-1 knockout 
mice show significantly decreased expression of both α glycoprotein hormone subunit 
（αGSU）and LHβ (Shinoda, Lei et al. 1995). Pitx1 is expressed in several anterior 
pituitary cell lineages and transactivates most of the anterior pituitary cell-specific genes 
(Tremblay, Lanctôt et al. 1998). Egr-1 is a zinc finger transcription factor that binds to a 
GC-rich sequence in DNA to activate gene transcription. Targeted disruption of Egr-1 
resulted in the selective loss of LH synthesis and secretion (Lee, Sadovsky et al. 1996).  
In contrast to the proximal promoter, the sequence of the distal region of the mammalian 
LHβ promoter is not well conserved across the species. Specificity protein 1 (Sp-1) and 
CArG binding sites have been identified in the distal domain of the rat LHβ  promoter 
sequence, while in the bovine LHβ promoter, the corresponding region is a nuclear 
transcription factor-Y (NFY) binding site instead (Kaiser, Sabbagh et al. 1998; Kaiser, 
Sabbagh et al. 1998; Weck, Anderson et al. 2000). The Sp-1 region in the rat LHβ 
promoter plays an important role in conferring GnRH responsiveness, while the role for 
NFY in mediating GnRH effect has not been established (Kaiser, Halvorson et al. 2000; 
Keri, Bachmann et al. 2000; Jorgensen, Quirk et al. 2004). The arrangement of above 
mentioned transcriptional factors is demonstrated in Figure 1.4(a). 
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1.2.1.2 Transcriptional machinery on the FSHβ promoter 
The mechanisms of the basal-level regulation of the FSHβ subunit gene are less well 
understood compared to LHβ gene. The Activator protein 1 (AP-1) factors, Jun and Fos, 
are early response genes, which are up-regulated rapidly by GnRH treatment, and have 
been implicated in the GnRH-induced regulation of FSHβ gene, reviewed by (Melamed, 
Kadir et al. 2006). Several potential binding sites for the Ap-1 factors have been 
identified on the mammalian FSHβ promoter, and some of which are shown to be 
functional. However, differences were seen in promoters from various species and/or 
under different experimental conditions (Miller, Shafiee-Kermani et al. 2002; Chong, 
Wang et al. 2004; Wang, Fortin et al. 2008). In the murine FSHβ promoter, a half Ap-1 
binding site is found to partially overlap with the nuclear factor Y (NFY)-binding site. 
But this phenomenon is not present in ovine and bovine FSHβ promoter (Coss, Jacobs et 
al. 2004). Another early response gene, Nur77, is also found on murine FSHβ promoter, 
and it plays an important role in regulating GnRH-induced de-repression of the murine 
FSHβ gene by recruiting other regulatory factors  (Lim, Luo et al. 2007). The 








Figure 1.4 Schematic representation of transcription factors on LHβ gene and FSHβ 
gene promoters.  
(a) On the LHβ gene proximal promoter each of Sp1, Egr1 and Sf1 has two binding sites, 
and pitx1 has one binding site. (b) On the FSHβ gene promoter, two Sf1 binding sites and 
an overlapped half Ap1 site with NFY site, a Nur77 binding site, and a pitx1 site are 
presented (Melamed, Kadir et al. 2006). 
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1.2.2 GnRH-induced regulation of gonadotropins 
The GnRH signaling is initiated by the interaction of GnRH with its cognate type I 
receptor, GnRHR, in pituitary gonadotropes and results in the activation of Gq/G11, 
phospholipase Cβ (PLCβI), PLA2, and PLD (Hsieh and Martin 1992). GnRHR activation 
induces activation of phospholipases C (PLC) and an increase in intracellular cyclic-
AMP (cAMP) levels (Bourne 1988). The elevated cAMP levels activate the downstream 
protein kinase A (PKA) (Yoshida, Hattori et al. 1975), while PLC accelerates the 
cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2). The cleavage consequently 
stimulates the production of inositol 1,4,5-trisphosphate (IP3) and  diacylglycerol (DAG) 
(Andrews and Conn 1986). IP3 induces the calcium release from the intracellular stores, 
and also extracellular calcium influx through L-type voltage-sensitive calcium channel 
(VSCC) (Naor 1990). DAG activates protein kinase C (PKC), which activates the 
downstream mitogen-activated proteins kinase (MAPK) pathways, including extracellular 
signal regulated kinase (ERK), c-jun NH2-terminal kinase (JNK) and p38 (Mitchell, Sim 
et al. 1994; Roberson, Zhang et al. 1999; Liu, Austin et al. 2002). Ca
2+
, together with 
various PKC isoforms, MAPKs and arachidonic acid (AA) metabolites serve as key 
nodes in the GnRH-stimulated signaling network that enable the gonadotropes to decode 
GnRH pulse frequencies and translate them into differential gonadotropin synthesis and 





Figure 1.5 Schematic representation of GnRH signaling in gonadotrope cells  
GnRH acts on the GnRHR and generates a set of selective interaction networks, which 
subsequently regulate the gonadotropin synthesis and secretion. It has been proposed that 
PKC, ERK, JNK, p38, Ca
2+
, c-SRC play as major key nodes in the interaction network 
maps. This drawing is adapted from Naor, Z (Naor 2009) with permission.    
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1.2.2.1 MAPK signaling pathways 
MAPK signaling pathways have pivotal roles including fate determination, differentiation, 
proliferation, survival, migration, growth and apoptosis (Pearson, Robinson et al. 2001). 
MAPK cascades are composed of up to six grades of protein kinases, which sequentially 
activate one another by phosphorylation (Seger and Krebs 1995) (Figure 1.6). Four major 
MAPK cascades in mammals are ERK 1-2 (p42 and p44), JNK 1-3, p38α-δ, and ERK5. 
They are also the most well studied signaling cascades induced by GnRH in gonadotrope 
cells. Previous studies have demonstrated that GnRH stimulates ERK, JNK, p38 and 
ERK5 in the gonadotrope cell lines (Naor, Benard et al. 2000; Benard, Naor et al. 2001; 
Bonfil, Chuderland et al. 2004).  
The hallmark of the MAPK family is their ability to translocate into the nucleus to 
activate transcription factors (Seger and Krebs 1995). ERK was found to translocate into 
nucleus by GnRH induction The nucleus translocation of ERK results in the 
phosphorylation and activation of various transcription factors such as c-Fos, c-Jun, 
ELK-1, Ets, STAT, CREB, histone H3, Egr1, and others (Liu, Austin et al. 2002; Bonfil, 
Chuderland et al. 2004; Caunt, Finch et al. 2006).  JNK and p38 both belong to stress 
activated proteins kinases (SAPKs), which are activated by stress stimuli, various GPCRs, 
inflammatory cytokines and growth factors. JNK cascade is initially activated by Rac1/ 
Cdc42, the activated signals are then transmitted through several MAP kinase kinases 
(MKKs) and finally activates several transcription factors such as c-Jun, ATF-2, NF-
ATc1, HSF-1, STAT3, and others. The p38 cascade is also initiated by Rac1/ Cdc42, and 
finally activates transcription factors such as ATF-1, ATF-2, MEF2A, SAP-1, Elk-1, 
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NFқB, Ets-1, CHOP, p53 and others (Seger and Krebs 1995; Pearson, Robinson et al. 
2001). 
The roles of PKC, Ca
2+
, and MAPK in regulating ganadotropin subunit gene expression 
are controversial. Murata's group claimed that JNK is involved in GnRH regulation of 
LHβ but not PKC and ERK (Yokoi, Ohmichi et al. 2000). However, Naor's group 
reported that PKC, ERK and JNK, but not Ca
2+, regulate LHβ gene expression (Harris, 
Bonfil et al. 2002). Similar controversial results were also reported for FSHβ gene 
(Bonfil, Chuderland et al. 2004). These conflicting results were likely due to different cell 





Figure 1.6 Schematic representation of the MAPK cascades.  
MAPK cascades consist of up to six tiers of protein kinases that sequentially activate one 
another by phosphorylation. LAD is an adaptor protein that activates ERK5; WNK is a 
MAP4K in ERK5 pathway; MOS is an oncogene that activates ERK; RSK serves as a 
MAPKAPK in the ERK1/2 pathway; MSK is a MAPKAPK that can be activated by both 
ERK and p38. This drawing is adapted from Naor, Z (Naor 2009) with permission.  
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1.2.2.2 Calcium signaling pathway 
Calcium ions (Ca
2+
) represent a ubiquitous intracellular second messenger with 
tremendous versatility (Berridge, Lipp et al. 2000). The versatility of Ca
2+
 is based on its 
binding kinetics, varying amplitude, spatial-temporal distribution and multiple cross talks 
with other signaling cascades. The most studied Ca
2+
 downstream pathway is MAPK 
pathway, which was induced by elevation of cytosolic Ca
2+
 levels caused by both calcium 
influx and mobilization from intracellular stores. Accumulating studies have found that 
Ca
2+
 is required for expression of gonadotropin genes (Naor 2009). Moreover, the 
intermittent changes in Ca
2+ 
has been suggested to be involved in decoding the GnRH 
frequency (Haisenleder, Yasin et al. 1997). Besides, Ca
2+ 
was also found to activate 
alternative downstream pathway, independent of MAPK. Calmodulin (CaM) is the most 
notable effecter, through interaction with various kinases, phosphatases and ion channels, 
mediating diverse Ca
2+
 downstream pathways (Chin and Means 2000; Means 2008; 
Swulius and Waxham 2008). In gonadotrope cells, so far there are two well characterized 
CaM downstream pathways; one is the CaM-dependent kinases (CaMKs) pathway, and 
the other is calcineurin pathway. Both of them have been found to mediating GnRH-





Figure 1.7 Schematic representation of Ca
2+
 signaling in gonadotrope cells. 
GnRH binding to GnRHR induces calcium influx (as well as mobilization: not shown) 
which activates CaM. The activation of CaM consequently stimulates the downstream 
effectors CaMKs and calcineurin, and results in the gonadotropin expression. This 




1.2.2.3 Wnt signaling pathway 
The WNT signaling controls numerous biological processes throughout development and 
adult life of all animals. Aberrant Wnt signaling underlies a wide range of pathologies in 
humans (Clevers and Nusse 2012). The WNT pathways are presented as two forms: the 
canonical Wnt/ β-catenin pathway and non-canonical Wnt pathways. The canonical Wnt/ 
β-catenin cascade is the best characterized Wnt signaling pathway, and β-catenin is the 
key effecter of this cascade. Without the stimulation of Wnt ligand on the Frizzled (FZD) 
family of receptors, β-catenin is captured by a destruction complex, which is composed 
of adenomatous polyposis coli and axin, bound by casein kinase I (CKI) and glycogen 
synthase kinase-3β (GSK-3β). GSK-3β phosphorylates β-catenin and targets it for 
ubiquitination and subsequent degradation via the proteasomal degradation pathway, and 
the cellular β-catenin amount is thus kept at a low level (Huelsken and Behrens 2002; 
Moon, Kohn et al. 2004; Nelson and Nusse 2004). The non-canonical Wnt cascades are 
less well characterized than their canonical counterpart. These pathways, including Wnt/ 
Ca
2+
 pathway and Wnt/c-JNK pathway, are also activated by Wnt ligands binding to FZD 
receptors, and are implicated to regulate the biological processes such as cell polarity, 
cytoskeleton reorganization and cell movement. A number of signaling mediators and 
transcription factors such as PKC, Ca
2+
/ CaM, calcineurine (CaN), Ca
2+
/ CaM-dependent 
Kinase II, nuclear factor of activated T cell (NFAT), dishevelled, RhoA, Rac, cdc42 and 
JNK  are involved in these cellular events (Kühl, Sheldahl et al. 2000; Ishitani, Kishida et 
al. 2003; van Es, Barker et al. 2003; Veeman, Axelrod et al. 2003; Kohn and Moon 2005; 
Katoh and Katoh 2007). Wnt ligands show chemical similarity to other secreted 
glycoprotein ligands, which function through G-protein-coupled receptors (GPCRs), and 
the Wnt signaling receptors, FZD family receptors, are seven-transmembrane-spanning 
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receptors that resemble GPCRs (Wang and Malbon 2003). In gonadotrope cells, GnRH 
has been indicated to target the Wnt signaling effecter, β-catenin, in the regulation of 
gonadotropins through coordination with Sf-1 (Salisbury, Binder et al. 2007). Since SF-1 
is a critical transcription factor, which is also required for the expression of other 
gonadotropin genes, thus β-catenin was proposed to also engage in mediating the GnRH 
response to other gonadotropin genes (Salisbury, Binder et al. 2008). GnRH also 
stimulates several known TCF target genes including Jun, Fra1, and Myc (Wurmbach, 
Yuen et al. 2001; Yuen, Wurmbach et al. 2002; Nateri, Spencer-Dene et al. 2005; 
Kikuchi, Kishida et al. 2006), among which Jun is another potential effecter mediating 
GnRH response to other gonadotropin genes. As Jun subunit is contained in the 
heterodimers protein AP1, which was known to mediate GnRH response to three 
gonadotrope signature genes: Cga, Fshβ, and Gnrhr (White, Duval et al. 1999; Norwitz, 
Xu et al. 2002; Coss, Jacobs et al. 2004; Xie, Bliss et al. 2005). The current knowledge of 





Figure 1.8 Schematic representation of GnRH-induced targeting of Wnt signaling. 
GnRH is known to target the canonical Wnt signaling protein, β-catenin, through 
stimulating β-catenin nuclear accumulation and consequently activating the TCF-
dependent transcription.  But the mechanism of which is not yet clear, possibly involves 
GSK-3β. GnRH also regulates the non-canonical pathways through activating Ca2+ 




1.3 High-throughput approaches to study regulation of gonadotropins 
Because of the complexity of GnRH signaling networks, several groups have applied 
high-throughput approaches to their study. Most of the earlier studies focused on the 
transcriptomic level. Extensive studies have been conducted by Sealfon’s group. They 
developed an early gene cDNA microarray technology, which was defined as FMA. They 
used FMA to characterize the time course from 1 to 6 h of gene responses occurred 
following activation of the GnRHR in LβT2 cells, and revealed a number of early 
responsive genes induced by GnRH. Their findings provide information regarding a 
number of signaling molecules and transcription factors which have potential roles to 
regulate gonadotropins by GnRH induction (Wurmbach, Yuen et al. 2001; Ruf, Fink et al. 
2003; Ruf and Sealfon 2004). Similar study was done by Shawn’s group who used GnRH 
agonist instead of GnRH to treat the LβT2 cells and employed a microarray analysis to 
identify genes regulated by GnRH agonist at 1 h and 24 h. They found many genes are 
associated with transcription regulation (Kakar, Winters et al. 2003). Later a microarray 
study of the genes stimulated by crosstalk of GnRH and activin were carried out. The 
experiment was designed to find out how GnRH-target genes are affected by activin 
pretreatment (Zhang, Bailey et al. 2006). The GnRH pulse frequency and amplitude on 
gonadotropin regulation in LβT2 cells was also studied by microarray in  a perifusion 
system, and a frequency-dependent change in gonadotropin gene expression was 
identified (Lawson, Tsutsumi et al. 2007). Melamed 's group utilized subtractive 
hybridization method to screen the altered genes by 8 h GnRH treatment  and identified 
genes crosstalk with estrogen signaling (Luo, Koh et al. 2005). These transcriptomic 
studies identified a number of signaling molecules and transcription factors, which 
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provided valuable clues to discover the mechanisms of transcriptional regulation of 
gonadotropins.  
However, the transcriptomic studies can only provide information on mRNA levels, 
while proteins are dynamic and constantly changing upon both external and internal 
stimuli (Anderson and Anderson 1998). Transcriptomic results cannot fully represent the 
state of a biological system such as the protein expression levels, the sub-cellular 
localization, and the post-translational modifications,  etc. Therefore, proteomic studies 
have become the more useful approaches in the post-genomic era, which has been applied 
extensively in cancer studies (Roesli, Elia et al. 2006; Batrakou, Kerr et al. 2009; 
Oeljeklaus, Meyer et al. 2009). So far, two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) technique is the only proteomic method that has been used 
for studying GnRH signaling in gonadotrope cells (Feng, Lawson et al. 2008). Feng et al. 
identified a few proteins involved in mRNA processing, suggesting the proteomic 
approaches are promising in exploring novel regulatory mechanisms in the regulation of 
gonadotropins other than transcriptional regulation.  
Gel-based technique, such as 2D-PAGE is the earliest developed and most frequently 
used method for protein profiling, where differentially expressed spots are excised and 
analyzed by mass spectrometry (MS). However, this method needs to perform a number 
of replicate experiments to minimize the experimental error (Righetti, Castagna et al. 
2004). Besides, the sensitivity of this method is not high, so it is difficult to detect low 
abundance proteins. Different gel electrophoresis (DIGE) is an alternative approach with 
the involvement of the fluorescence dyes, used for labeling up to 3 different samples 
(Lilley, Razzaq et al. 2002). However, the gel-based approach has considerable 
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limitations. The following groups of proteins will be poorly represented on a 2D gel: 
proteins with extreme pIs or molecular weight, low abundance proteins, and hydrophobic 
membrane proteins. Due to the limitations of gel-based approach, quantitative non-2D 
gel-based technologies have been developed and they have become more and more 
routine and have the potential to give information about subsets of proteins missing from  
the 2D gel approach (Lilley and Dupree 2006). 
Liquid chromatography (LC)-based approaches allow the combination of stationary and 
mobile phase for the separation of complex biological samples at the protein or peptide 
level (Shi, Xiang et al. 2004; Issaq, Chan et al. 2005). For the quantitative profiling of 
proteins, several stable-isotope labeling methods are developed based on LC-mass 
spectrometry (MS), among which two frequently used methods are isotope-coded affinity 
tags (ICAT) and isobaric tag for relative and absolute quantitation (iTRAQ). 
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1.4 High-throughput proteomic approaches 
1.4.1 Mass Spectrometry  
Mass spectrometry is a potent analytical technique used to identify unknown compounds, 
to quantify known compounds, and to elucidate the structure and chemical properties of 
molecules (Thelen and Miernyk 2012). The fundamental principle of mass spectrometry 
is to measure the masses of molecules through measuring their mass-to-charge (m/z) 
ratios to confirm the identity of a molecule. A typical mass spectrometer is composed of 
an ionizer that volatizes and ionizes the analytes, a mass analyzer that measures m/z of 
the ionized analytes, and a detector that records the number of ions at each m/z value. The 
ions are sorted and separated depending on their mass and charge ratio, and then detected 
and the results are subsequently shown as a readable or graphic display (Horning, Carroll 
et al. 1977).  
Electrospray Ionization (ESI) and Matrix Assisted Laser Desorption Ionization (MALDI) 
are the two most popular ionization techniques for macromolecules. ESI ionizes the 
analytes out of a solution and therefore coupled with liquid-based separation tools (Figure 
1.9). While, MALDI sublimates and ionizes the samples out of a dry, crystalline matrix 
through laser pulses (Figure 1.10). MALDI-MS is preferred for analyzing relatively 
simple peptides mixtures, while integrated liquid-chromatography (LC) ESI-MS is 
preferred for analyzing complex samples (Aebersold and Mann 2003). 
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Figure 1.9 Schematic representation of ESI.  
A liquid sample solution passes through a nozzle with a very high voltage; the charged 
liquid in the nozzle becomes unstable as it is forced to hold more and more charges. After 
reaching a critical point, the liquid blows apart into highly charged droplets, at the tip of 
the nozzle (Kebarle and Tang 1993). 
 
Figure 1.10 Schematic representation of MALDI. 
During MALDI, the analyte molecules are ejected by laser pulses from the sample co-




ICAT labeling reagents have three major components: a biotin affinity tag, which is used 
to isolate ICAT-labeled peptides; an isotopically coded linker, which can be 
differentiated by MS; and a reactive group with specificity towards thiol groups of 
cysteines (Gygi, Rist et al. 1999). Cysteine is a wide coverage but rare amio acid. Around 
90 % of mouse proteins have at least 1 cysteine residue; however the occurrence of 
cysteines in proteins is only 2 % (Miseta and Csutora 2000).  The composition of ICAT 
reagent is demonstrated in Figure 1.11(a). The reagents exist in two forms: heavy and 
light. In the 1
st
 genration of ICAT reagents, the heavy form contains 8 deuterium and the 
light form contains no deuterius in the isotopically coded linker, allowing an 8 Da mass 
difference, which provides discrimination between two samples used for relative 
quantitation. While in the new generation of ICAT reagents, cleavable ICAT (cICAT) 
reagents, C
13
 is used to replace deuterium for creating a heavy reagent resulting in a 9 Da 
mass difference between heavy and light forms. Additionally, the biotin tag is connected 
to the rest of the molecule through an acid-cleavable linker. Figure 1.11(b) shows the 
strategy of ICAT experiment. After the two samples are labeled with ICAT reagents, they 
are combined and digested with trypsin to peptides. The excess reagents are removed 
through cation exchange chromatography followed by an avidin affinity purification step. 
The relative quantitation is then determined by the ratio of signal intensities of each 
peptide pairs (Shiio and Aebersold 2006). In the 1
st
 generation ICAT labeling, the light 
and heavy ICAT labeled peptides were found to exhibit different retention times on 
reverse phase HPLC columns. Furthermore, the retention of the biotin tag complicates 
tandem MS interpretation (Zhang and Regnier 2002). To overcome these problems, the 
2
nd
 generation of ICAT was developed. Compared to the 1
st
 generation ICAT reagent, the 
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new generation allows the co-elution of heavy and light ICAT-labeled peptides, which 
resolved the problem of retention time difference.  
The most advantage of ICAT strategy is that the complexity of the peptide mixture is 
greatly simplified because only the cysteine-containing peptides are isolated and enriched, 
thus allowing the detection of the low abundance proteins. However, the specificity of the 
ICAT reagents for cysteine although contributing to simplify analysis of peptide complex, 
is also one of the drawbacks as this strategy can only be applied to cysteine-containing 
proteins. While many regulatory proteins, especially those with post-translational 





Figure 1.11 The ICAT strategy for proteomics experiment. 




iTRAQ labeling is a more recently developed proteomic approach by Darryl Pappin and 
colleagues at Applied Biosystems in 2004 (Coss, Jacobs et al. 2004). iTRAQ reagents are 
a group of amine-specific isobaric reagents, which can be used to identify and quantify 
up to eight different samples simultaneously. Each isobaric tag is composed of a charged 
reporter group, a peptide reactive group, and a neutral balance portion to keep an overall 
mass of 145 for 4-plex iTRAQ reagents or 305 for 8-plex iTRAQ reagents (Figure 1.12 
(a)). The reporter group is unique to each of the 4 (114--117) or 8 (113-121) reagents, 
which give rise to unique reporter ions upon MS/MS fragmentation for quantitation. The 
peptide reactive group is able to react with all primary amines, including the N-terminus 
and the ɛ-amino group of the lysine side chain. Thus this method enhances peptide 
coverage for any given protein while keeping other important information such as  PTMs 
(Zieske 2006). The general workflow is described in Figure 1.12 (b) for 4-plex iTRAQ 
analysis. Individual samples are reduced, alkylated and trypsin-digested. The resulting 
peptide mixture is subsequently parallel-labeled with iTRAQ reagents provided by the 
multiplex set. The labeled peptides are then combined and subjected to LC-MS/MS 
analysis. The development of the iTRAQ strategy expands the application of comparative 
proteomics to numerous experimental approaches such as time-course analysis (Petti, 
Thelemann et al. 2005), affinity pull down analysis (Wu, Warren et al. 2010), and disease 
markers identification (DeSouza, Diehl et al. 2005).  In addition, as most of the peptides 
in a sample are conformable to iTRAQ labeling, there will be less information loss 
compared to ICAT labeling. Hence, this strategy increases the chance to identify the 
proteins containing PTMs. Finally, the multiplexity of the reagents provides the 




Figure 1.12 The iTRAQ strategy for proteomics experiment. 
(a) Structure of the iTRAQ reagent 4-plex (total mass=145) and 8-plex (total mass=305); 
(b) Schematic representation of 4-plex iTRAQ-labeling based experiment. 
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1.4.4 Bioinformatics analysis of gene function 
The development of high-throughput profiling technologies gives rise to the development 
of knowledge-based pathway analysis, which is able to extract the meaning from a long 
list of genes and proteins. The main idea of the system-wide data analysis approach is a 
knowledge base that contains extracted literature information used for functional data 
analysis and network generation (Ganter, Zidek et al. 2007). A number of knowledge 
bases help researcher to investigate the biological processes, cellular components, and 
molecular functions related to their experimental dataset.  
Ingenuity pathway analysis (IPA) is a commercial pathway analysis tool. It was designed 
to meet the requirement of a comprehensive application purpose from the fundamental 
core analysis to more specific metabolic, biomarker, and toxicity analysis (Khatri, Sirota 
et al. 2012). Search Tool for the Retrieval of Interacting Genes (STRING) http://string-
db.org/ is an open source pathway analysis tool. It allows the analysis and search for 
comprehensive functional association between the proteins. The functional association is 
deduced by both experimental and predicted information. And most importantly, it is 
provided with a confidence score, and supplemental information such as protein domain 
and 3D structure. All these above information can be obtained within one stable and 
consistent identifier space (Szklarczyk, Franceschini et al. 2011). Database for 
Annotation, Visualization and Integrated Discovery (DAVID) gene functional 
classification tool http://david.abcc.ncifcrf.gov/ is another useful open source program to 
analyze gene function. It uses a novel algorithm, to compile a list of genes or associated 
biological terms into biological modules, which refer to the organized classes of related 
genes or biology. This organization is achieved by looking for the complex biological co-
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occurrences occurring in multiple sources of functional annotation. It is a powerful tool to 
group the functionally associated genes and terms into a manageable number of 
biological modules, which can then be efficiently used to interpret the list of genes in a 
network context (Huang, Sherman et al. 2007).  
Although these bioinformatics approaches are greatly helpful in extracting and explaining 
the underlying biology for high-throughput molecular measurement, the limitation of 
these approaches also needs to be addressed. One obvious problem is that the true 
pathway topology is quite cell-contextual dependent. For example, GnRH induced 
MAPK activation has been found varied among different pituitary cells (Dobkin-Bekman, 
Naidich et al. 2006). Recently, an open source knowledgebase of the GnRHR signaling in 
the LβT2 cells was developed by using 106 relevant publications (Fink, Pincas et al. 
2010). Compared to the IPA pathway analysis, this pathway analysis method more 
specifically depicted the GnRH signaling in gonadotrope cell. However, due to the 
limited space on the pathway map, this knowledgebase doesn’t include the modification 
events, which are considered to play pivotal roles in regulating a wide range of biological 
processes.  
1.5 Murine gonadotrope cell lines 
Studies of the regulation of gonadotropin genes and GnRH signaling have been the 
subject of intense experimental investigation for the past 25 years, by means of both in 
vivo and in vitro approaches. In vitro models have mainly consisted of pituitary primary 
cultures, heterologous cell systems, and the gonadotrope cell lines αT3-1 and LβT2 (Fink, 
Pincas et al. 2010). Because pituitary gonadotropes account for only 5-10% of the 
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anterior pituitary cell population, using primary cultures as a model for the study of 
gonadotrope-specific events is challenging.  
The gonadotrope cell lineage originates in the ventral part of the embryonic pituitary. The 
expression of the α-subunit gene is observed at approximately embryonic day 11.5 (e11.5) 
of gestation in the mouse (Japon, Rubinstein et al. 1994) followed by the expression of 
the individual β-subunits of LH on e16.5 and FSH on e17.5. The immortalized 
gonadotrope cell lines αT3-1 and LβT2 were obtained by directed oncogenesis in 
transgenic mice. The αT3-1 cell line was generated through targeting expression of the 
SV40 large T antigen using the regulatory region of the human glycoprotein hormone α-
subunit gene (Windle, Weiner et al. 1990), and the LβT2 cell line was, in turn, generated 
through targeting oncogenesis with the 5’-flanking region of the LHβ gene (Alarid, 
Windle et al. 1996). The αT3-1 cell line represents an immature gonadotrope that is not 
fully differentiated and expresses the glycoprotein hormone α-subunit, responds to GnRH, 
but does not express the LHβ and FSHβ subunits (Windle, Weiner et al. 1990). In 
contrast, the LβT2 cell line displays the characteristics of a fully differentiated 
gonadotrope: in addition to  α-subunit, it expresses LHβ, FSHβ, GnRHR, activin, inhibin, 
follistatin and steroid receptors (Windle, Weiner et al. 1990; Alarid, Windle et al. 1996; 
Turgeon, Kimura et al. 1996; Graham, Nusser et al. 1999; Hammer, Krylova et al. 1999) 
(Figure 1.13). Consequently, these two cell lines represent useful model for the study of 
FSHβ and LHβ gene-specific transcription mechanisms at both basal and GnRH-
regulated levels.  
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Figure 1.13  Schematic representation of the gonadotrope cell lineage development 
in mouse.  
The initiation of anterior pituitary differentiation is marked by the expression of the 
glycoprotein hormone α subunit gene. The emergence of mature gonadotrope happens in 
two stages, with the expression of LHβ and FSHβ subunit genes on e16.5 and e17.5, 
respectively. These temporal and distinct stages of differentiation were applied by target 
oncogenesis in transgenic mice to generate immortalized immature and mature pituitary 
αT3-1 and LβT2 cell lines (Alarid, Windle et al. 1996). 
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Chapter 2. Aims of study 
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GnRH is the first key hormone of reproduction. The binding of GnRH to its cognate type 
I receptor initiates diverse signaling cascades. Among them, the MAPK signaling 
cascades are the most studied and characterized. The GnRH-induced MAPK downstream 
signaling enables the gonadotrope to response to GnRH and translates the signals into 
differential gonadotropin synthesis and secretion.  
Through utilizing high-throughput transcriptomic approaches, a number of transcription 
factors have been revealed to mediate GnRH-induced transcriptional regulation of 
gonadotropins. However, the gene regulations not only occur at the transcriptional level 
but also at the post-transcriptional, translational and posttranslational levels. Therefore, 
we would like to perform high-throughput proteomic studies in order to identify those 
factors involved in the regulations after transcription. Besides MAPK signaling cascades, 
recent studies indicate that GnRH-induced gonadotropin production may also be 
regulated through other signaling pathways. However, the current knowledge in this field 
is still rather limited. Only a few genes have been identified, which are insufficient to 
elucidate an integrative map. So there is a need to identify more genes/proteins in order to 
elucidate those signaling pathways. Furthermore, nowadays the study of GnRH signaling 
is no longer staying at a static status, but rather moving to the GnRH pulse frequency 
induced differential regulation of gonadotropins. How the gonadotropins decode the 
GnRH frequency is still a mystery. 
The main aims of the project are: 
55 
1) To identify low abundance signaling molecules. Whole cell lysate from mock-
treated and GnRH-treated LβT2 cells were compared by cICAT-based proteomics 
experiment. 
2) To functionally validate the candidates identified by cICAT proteomic profiling, 
and propose signaling pathways based on the findings. 
3) To identify the proteins involved in posttranscriptional, translational and 
posttranslational regulation of gonadotropins. Nuclear cell lysate from mock-
treated and GnRH-treated LβT2 cells were compared by iTRAQ-based 
proteomics experiment. 
4) To functionally validate the most prominent proteins identified by iTRAQ 
proteomic profiling. 
5) To identify the proteins induced by different GnRH frequency treatment, and 
predict their functional correlation with the GnRH frequency. 
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Chapter 3. Materials and methods 
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3.1 Cell culture 
3.1.1 Growth condition  
LβT2 cells (generously provided by Dr. P. Mellon, University of California, San Diego, 
USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) 
supplemented with 10 % certified fetal calf serum, 10 mM HEPES (pH 7.4), 100 U/ml 
penicillin and 100 µg/ml streptomycin, which were purchased from Invitrogen (Carlsbad, 
CA, USA), and were incubated at 37 °C under 5 % CO2.  
3.1.2 GnRH treatment of cells  
LT2 cells were first starved 12 h in Modified Eagle Medium (MEM; Gibco) starvation 
medium, supplemented with 10 mM HEPES (pH 7.4), 100 U/ml penicillin and 100 µg/ml 
streptomycin, 1 % Essential Amino Acid (Gibco), 1 % Sodium Pyruvate (Hyclone), and 
then treated with either 100 nM GnRH ([D-Ala6]-LHRH; Sigma; dissolved in DMSO) or 
mock (DMSO)-containing MEM starvation medium for either 4 h or 30 min.   
3.1.3 Transient transfection 
Transfection was carried out at 70-80 % confluence after cells were plated overnight.  
LβT2 cells were transfected using either GenePORTER 2 (Gene Therapy Systems) or 
Lipofectamine 2000 (Invitrogen) Transfection Reagent. The optimized transfection 
conditions were shown in Table 3.1. For GenePORTER2 transfection, the hydrated 
GenePORTER 2 reagent was first mixed with serum-free MEM and the DNA plasmids 
were incubated with DNA diluent at room temperature (RT) for 5 min, and then they 
were mixed together and further incubated for 10min at RT before they were added to the 
cells. For Lipofectamine transfection, both the Lipofectamine 2000 reagent and the DNA 
plasmids were mixed with serum-free MEM in separate eppendorf tubes. After 5 min 
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incubation at RT, the DNA solution was added to the diluted Lipofectamine2000 reagent 
and further incubated for 20 min at RT before they were applied to the cells. 
















Culture Vessel 96-well 24-
well 
6-well 60-mm 100-mm 
DNA (ul) 0.1-0.5 2 6 8 12 
DNA diluents (ul) 0.5-2.5 50 150 200 300 
Gene PORTER2(ul) 2.5 10 30 40 60 
SFM(MEM) (ul) 2-10 40 120 160 240 
DMEM Culture 
Medium (ul) 
100 250 1000 2500 5000 
Culture Vessel 6-well 
DNA (ul) 4 
Lipofectamine 2000 (ul) 9 
SFM(MEM) (ul) 125 
DMEM Culture Medium (ul) 100 
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3.2 Sample preparation and protein quantitaion 
3.2.1 Sample preparation for ICAT study 
3.2.1.1 Whole cell lysate preparation  
The mock-treated and GnRH-treated LβT2 cells were rinsed with PBS for 3 times, and 
were detached from culture dishes by 1 ml of 0.5 mM EDTA. The cells were blew off 
from culture dishes using PBS, and collected by centrifugation (Eppendorf 5810R) at 
3500 rpm for 10 min at 4C. The packed cell volume (pcv) was measured and the cells 
were resuspended in ICAT lysis buffer, which is composed of 0.5 M triethylammonium 
bicarbonate buffer (TEAB) (Sigma), 1 % SDS with supplement of cocktail proteinase 
inhibitors (Roche) and phosphatase inhibitors (Sigma), to a final volume of 4 pcv. The 
cells were swelled on ice for 10 min, and homogenized with 15 up-and-down strokes in a 
glass Dounce homogenizer (Sigma). The cell lysate was heated at 97 C for 10 min, and 
the cell debris was removed by ultracentrifugation (Beckman Optima
TM
 TLX) at 25000 
rpm for 30 min at 4 C, and the supernatant was stored at -80 C for further application. 
3.2.1.2 RC-DC quantitation 
The protein concentration was determined by RC-DC quantitation (Biorad). All the 
procedures were done following the protocol provided by the RC-DC quantitation kit. 
BSA stock solution was prepared by reconstitute BSA powder (Sigma) in ICAT lysis 
buffer at 2 mg/ml.  BSA standard curve was plotted using 5 consecutive dilutions (0, 0.2, 
0.4, 0.8, 1.2, 1.5 mg/ml) of the BSA standard in ICAT lysis buffer. Three replicates were 
prepared for each dilution. Total protein lysate was diluted 8-fold using ICAT lysis buffer, 
and the concentration was determined based on the equation derived from the BSA 
standard curve. 
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3.2.2 Sample preparation for iTRAQ study 
3.2.2.1 Separation of nuclear and cytoplasmic proteins  
All the buffers mentioned in this section were listed in Table 3.2. The cell pellet was 
collected as described in 3.2.1.1, and was rapidly resuspended in 5 pcv of hypotonic 
buffer, and centrifuged at 4500 rpm for 5 min at 4 C. The supernatant was discarded and 
the packed cells were resuspended again in 3 pcv of hypotonic buffer. After swelling on 
ice for 10 min, the cells were homogenized with 15 up-and-down stokes in a glass 
Dounce homogenizer and pelleted down at 6000 rpm for 15 min at 4 C. The supernatant 
was saved for cytoplasmic extract preparation, and the pellet was used for further nuclear 
protein extraction. 
Cytoplasmic proteins were extracted from the supernatant by adding 0.11 pcv of 10× 
cytoplasmic extract buffer. The mixture was mixed thoroughly by vortexing and pelleted 
down by ultracentrifugation at 50,000 rpm for 1 h at 4 C. The supernatant was saved for 
further desalting.  
The nuclei pellets were resuspended in low-salt buffer equal to ½ packed nuclear volume 
(pnv), and drop-wisely mixed with ½ pnv of high-salt buffer. The nuclear protein was 
extracted by 10 s vortexing every 5 min for up to 30 min. The extracted nuclei were 
pelleted down by ultracentrifugation at 25,000 rpm for 30 min at 4 C. The supernatant 
was saved for further desalting.  
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Hypotonic buffer 10 mM HEPES, pH 7.9 at 4 C 
1.5 mM MgCl2 
10 mM KCl 
0.5 mM DTT 
cocktail proteinase inhibitors 
phosphoproteinase inhibitors 
Low salt buffer 20 mM  HEPES, pH 7.9 at 4 C 
25 % glycerol 
1.5 mM MgCl2 
0.2 mM EDTA 
0.5 mM DTT 
cocktail proteinase inhibitors 
phosphoproteinase inhibitors 
High salt buffer 20 mM  HEPES, pH 7.9 at 4 C 
25% glycerol 
1.5 mM MgCl2 
800 mM KCl 
0.2 mM EDTA 
0.5 mM DTT 
cocktail proteinase inhibitors 
phosphoproteinase inhibitors 
Cytoplasmic 
extract buffer, 10× 
300 mM  HEPES, pH 7.9 at 4 C 
1.4 M KCl 
30 mM MgCl2 




Sample desalting was carried out using the centrifugal filter devices YM-3, Microcon 
(Millipore). The raw samples from cytoplasmic and nuclear extraction were added to the 
sample reservoirs together with the iTRAQ lysis buffer, 0.5 M TEAB + 0.1 % SDS. The 
high salt buffer which was contained in the original samples was gradually replaced by 
repeated filling the sample reservoir with iTRAQ lysis buffer and continuous 
centrifugation at 14,000 g, 4 C. 
3.2.2.3 Bradford quantitation 
The protein concentration was determined by Bradford quantitation method (Biorad). All 
the procedures were done following the protocol provided by the Bradford quantitation 
kit. BSA stock solution was prepared by dissolving BSA powder (Sigma) in iTRAQ lysis 
buffer at 20 mg/ml, and further diluted to 1 mg/ml in H2O. BSA standard curve was 
plotted through 6 consecutive dilutions (0, 100, 125, 150, 175, 200, 225 µg/ml) of BSA 
standard. Three replicates were prepared for each dilution. Protein samples were diluted 
20-fold with H2O, and their concentrations were determined based on the equation 
derived for the BSA standard curve. 
3.2.3 Calibration of protein quantitation by silver staining 
After quantitation by either RC-DC or Bradford method, protein concentrations were 
further confirmed with silver staining. 1 µg of each sample was resolved with the SDS-
PAGE gel and silver-stained. The recipe and procedure of silver staining steps were 
shown in Table 3.3. The protein concentration was then finely adjusted according to the 
silver staining result. 
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Buffers (for 1pcs gel) Component (for 25ml solution) 
Fixing buffer 50 % methanol 
12 % acetic acid 
12.5 ul of 37 % formalin 
 
55 rpm RT 30 min 
Washing buffer 1 35 % ethanol 
 
55 rpm 3*20 min  
Sensitizing buffer 0.02 % sodium thiosulphate 
 
80 rpm 2 min 
Washing buffer 2 H2O 
 
55 rpm 3*5 min 
Silver buffer 0.2 % silver nitrate  
19 ul of 37 % formalin 
 
80 rpm 20 min 
Washing buffer 3 H2O 
 
55rpm 2*1min 
Developing buffer 6 % sodium carbonate 
0.0004 % sodium thiosulphate 
12.5 ul of 37 % formalin 
 
110 rpm until band appears 
Stopping buffer 25 mM Sodium EDTA 
 
110 rpm 20 min 
Washing buffer 4 H2O 
 
55 rpm 3*5 min Store at 4 C 
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3.3 Quantitative proteomics using Stable-Isotope labeling technologies 
3.3.1 Cleavable Isotope Coded Affinity Tag (cICAT) labeling 
cICAT labeling and processing of the samples were carried out according to the kit 
instruction (AB SCIEX). After quantitation, 100 μg of proteins from each of the control 
(labeled with cICAT light) and GnRH-treated cell lysate (labeled with cICAT heavy)  
were reduced with 1.25 mM Triscarboxyethylphosphine (TCEP), and subsequently 
labeled with the isotopic light- and heavy- forms of the cICAT reagents respectively for 2 
h at 37 C in the dark.  Each pair of heavy- and light-cICAT-labeled proteins were then 
combined and trypsinized at 37 C for 16 h. Upon completion of in situ digestion, the 
digested peptide mixture was passed through a strong-cation exchange cartridge, and then 
enriched with an avidin affinity cartridge. The cICAT-labeled peptides were then dried 
by a SpeedVac concentrator (Savant) and re-dissolved in cleaving reagents and incubated 
at 37 C for 2 h. After the removal of biotin, peptides were desalted using Sep-Pak C18 
cartridges (Waters) followed by lyophilization before being reconstituted for 2-
Dimensional liquid chromatography (2-D LC).  
3.3.2 Isobaric Tag for Relative and Absolute Quantification (iTRAQ) labeling 
8-plex iTRAQ labeling of each sample was performed as described in manufacturer’s 
protocol (AB SCIEX). A total of 100 μg proteins from each mock-treated and GnRH-
treated sample were reduced with 5 mM TCEP at 60 C for 1 h, and then alkylated with 
10 mM methyl methanethiosulfonate (MMTS) for 10 min. After cysteine blocking, each 
sample was diluted to 0.05% (w/v) SDS before trypsin digestion at 37 C for 16 h. Each 
digested sample was then labeled for 1 h with one of the eight isobaric amine-reactive 
tags. These 8-plex iTRAQ-labeled samples were then pooled and passed through a 
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strong-cation exchange (SCX) cartridge as recommended by the manufacturer (AB 
SCIEX). The eluate was subsequently desalted using a Sep-Pak cartridge (Waters). 
Finally each sample was lyophilized and reconstituted for 2-D LC analysis. 
3.3.3 2-D LC and Mass Spectrometry (2D-LC MS/MS) 
Each of the cICAT and iTRAQ-labeled peptide mixtures was reconstituted in 2 % (v/v) 
acetonitrile (ACN) with 0.05 % (v/v) trifluoroacetic acid (TFA) and after centrifugation 
the supernatant was separated using an Ultimate
TM
 dual-gradient LC system (Dionex-LC 
Packings) equipped with a Probot
TM
 MALDI spotting device. In the first dimensional 
separation, the labeled peptide mixture was first injected into a SCX column (300 µm i.d., 
× 15 cm, packed with 10 µm POROS 10S; Dionex-LC Packings) at a flow rate of 6 
μl/min. Nine fractions were obtained using step gradients of mobile phase B buffer: 
unbound, 0-5, 5-10, 10-15, 15-20, 20-30, 30-40, 40-50, 50-100 % of B. In the second 
dimensional separation, the eluted fractions were captured alternatively onto two 
PepMap
TM
 trap columns (300 μm i.d.,  × 1 mm, packed with 5 μm C18, 100 Å; Dionex-
LC Packings) and washed with 0.05% TFA followed by gradient elution to a reverse-
phase (RP) Monolithic Capillary column (200 μm i.d., × 5 cm; Dionex-LC Packings). 
The LC fractions were mixed with matrix-assisted laser desorption/ionization (MALDI) 
matrix solution at a flow rate of 5.4 μl/min via a 25 nl mixing-tee (Upchurch Scientific) 
before they were spotted in 28 X 44 spot arrays on 123 × 81 mm Opti-TOF LC-MALDI 
inserts (AB SCIEX) using a Probot Micro Precision Fraction collector (Dionex-LC 
Packings) at a speed of 1 spot per 5 sec. The buffers used in 2D-LC MS/MS were shown 
in Table 3.4. 
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5 mM KH2PO4,  pH 3 
5% ACN 
Mobile phase B 
(1st-dimensional) 
 
5 mM KH2PO4,  pH 3 
5 % ACN 
500 mM KCl 




2 % ACN 
0.05 % TFA 




80 % ACN 
0.04 % TFA 
MALDI matrix  
solution 
7 mg/ml α-cyano-4-hydroxycinnamic acid (CHCA) 
130 μg/ml ammonium citrate in 75 % ACN 
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3.3.4 Tandem Mass Spectrometric analysis  
The MS and MS/MS of ICAT samples were analyzed using an ABI 4800 Proteomics 
Analyzer (AB SCIEX) with a MALDI ionization source and TOF/TOF optics operating 
in MS-positive reflector mode. Laser intensity was set to 4000 for MS and 4300 for 
MS/MS acquisition. For MS analysis, typically 1000 shots were accumulated for each 
sample well. Tandem MS/MS analyses were performed using nitrogen at collision energy 
of 2 kV and a collision gas pressure of ~1 X 10
-6 
Torr. 2000-5000 shots were combined 
for each spectrum depending on the quality of the data. 
The MS analysis of iTRAQ samples were analyzed using an ABI 5600 TripleTOF 
analyzer (QqTOF; AB SCIEX) operating in information dependent mode. The mass 
range of 400-1800 m/z with 250 ms accumulation time for each spectrum was used for 
selecting the precursor ions. From each MS spectra, a maximum of 20 precursors were 
selected per cycle for MS/MS analyses with 100 ms minimum accumulation time for 
each precursor and dynamic exclusion for 15 s. Tandem MS was recorded in a high 
sensitivity mode with both rolling collision energy and iTRAQ reagent collision energy 
adjustment on.  
3.3.5 Peptide and protein identification 
Protein identification and ICAT quantification were performed with the GPS Explorer
TM
 
software Ver. 3.6 (AB SCIEX) using the MASCOT search engine (V2.1; Matrix Science) 
and normalized against median ratio obtained from all the cICAT peptide pairs detected 
in one sample. The ratios were calculated based on the cluster areas of the heavy-cICAT 
labeled peptides and those of the light-cICAT labeled peptides.  The International Protein 
Index (IPI) mouse database (v3.75) was used for the search of tryptic peptides. 
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Protein identification and iTRAQ quantification were performed with ProteinPilot™ 
Software 4.2 (AB SCIEX) using the Paragon™ algorithm for the peptide identification, 
which was further processed by Pro Group
TM 
algorithm that allows the isoform-specific 
quantification to differentiate the expression between various isoforms. The user defined 
search parameters were as follows: (1) Sample type, iTRAQ 8plex (Peptide labeled); (2) 
Cysteine alkylation, MMTS; (3) Digestion, Trypsin; (4) Instrument, TripleTOF5600; (5) 
Special factors, None; (6) Species, Mus musculus; (7) ID focus, Biological modifications; 
(8) Database, ipi.MOUSE.v3.87.fasta; (9) Search effort, Thorough; (10) FDR Analysis: 
Yes; (11) User modifies parameter files: No. The peptide list obtained from 
ProteinPilot
TM
 was exported to Microsoft Excel for further analysis. The peptides for 
quantitation were automatically selected by the software, by removing those with shared 
MS/MS, low confidence, weak signal or discordant peptide type, to calculate the reporter 
peak area, error factor (EF) and p value. The resulting data were set as auto bias-




3.3.6 Determination of the significant cut-off threshold for fold-change 
The significant cut-off threshold for ICAT dataset was determined using the standard 
deviation (S.D.) method as described by Tan et al. (Tan, Tan et al. 2008). Thus, the cut-
off threshold for cICAT labeled peptides was set as >1.3 for up-regulated proteins and 
<0.77 for down-regulated proteins.  
The significant cut-off threshold for iTRAQ dataset was determined using a more 
stringent method, biological replicate method, which has been described by Gan et al. 
(Gan, Chong et al. 2007). Briefly, the numbers of the proteins fell in each of the 
cumulative percentage coverage (0 % to 100 %) were plotted against the corresponding 
percentages of variation (5 % to 80 %). By doing this, around 48% variation was found to 
corresponding to 88% coverage of data, therefore the final cutoff was fixed at 1.5 fold 
(±50 % variation), which corresponds to >1.5 for up-regulation and <0.67 for down-
regulation.  
3.3.7 Estimation of false positive rate to determine cut-off score 
For ICAT dataset, a randomized database created using IPI mouse database Version 3.75 
was also used to search the cICAT-labeled peptides. The False Positive Rate (FDR) was 
calculated by comparing the search results from the randomized database versus the 
actual database. The minimum ion score confidence interval (C.I.) % was set as the value 
at which no more than 5 % FDR was achieved. Based on this cut-off threshold, all the 
proteins identified from the random database search were single-peptide matched. For 
single-peptide matched proteins, only those with ion score C.I. % greater than the highest 
C.I. % attained from the random database search were selected as significant. For iTRAQ 
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dataset, the cut-off for unused proteins score was calculated as ≥ 1.3, corresponding to 
95 % C.I., was used as the first quantification criteria. 
3.3.8 Bioinformatics analysis 
Ingenuity Pathway Analysis (IPA) software (http://www.ingenuity.com) and Core 
Analysis module was selected to analyze the top biological processes as well as 
molecular and cellular functions. The reference set and parameters for IPA were shown 
as follows: (1) Reference set, Ingenuity Knowledge Base (Genes only); (2) Relationship 
to include, Direct and Indirect, Includes Endogenous Chemicals; (3) Filter Summary, 
Consider only relationships where confidence=Experimentally Observed OR High 
(predicted).  
The open source program DAVID (http://david.abcc.ncifcrf.gov/) was used to analyze the 
top-ranked molecular functions among a given list of proteins using the mouse genome as 
reference. After uploading all the protein IDs, the IPI_ID was chosen as the identifier, 
and Gene list was chosen as the list type, and the list was submitted to the software server. 
Under the “Functional _categories” panel, “SP-PIR_KEYWORDS” was selected for the 
functional characterization analysis. The GO was reported with a Benjamini (FDR 
corrected) p-value <0.05.  
The open source STRING ( http://string-db.org/) was used to identify the top interaction 
networks among the significantly altered proteins. After uploading all the protein IDs into 
the software server, the "GO enrichment" panel was selected and the top terms were 
looked for under each of the biological processes, molecular functions and cellular 
components and subsequently the protein IDs were exported from each selected terms. 
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And then the protein IDs from each top terms were uploaded again and the actions view 
was selected to check the interaction maps including nodes (individual proteins) and 
edges (biological relationship between nodes).  
3.4 RT-PCR analysis 
3.4.1 RNA extraction and reverse transcription for cDNA synthesis 
RNA isolation from LβT2 cells was performed using Trizol (Invitrogen) according to the 
manufacturer's instruction. First the cells were incubated with the Trizol reagent (1 ml of 
Trizol for 6-well plate, 3 ml of Trizol for 60 mm plate) for 5 min at RT to allow 
dissociation of the nucleoprotein complex, and then 0.2 ml of chloroform (Merck) per 1 
ml of Trizol reagent was added for homogenization. After vigorous vortexing for 15 sec, 
the mixture was incubated for 3 min at RT. The RNA aqueous phase was separated by 
centrifugation at 12,000 g for 15 min at 4 C, and transferred by pipetting to a new tube. 
The RNA present in the aqueous phase was further precipitated by 0.5 ml isopropanol 
(Sigma) per 1 ml Trizol reagent followed by centrifugation at 12,000 g for 10 min at 4 C.  
RNA pellet was washed with 1 ml of 75% ethanol and collected by centrifugation at 
7,500 g for 5 min at 4 C. The purified RNA was then dried and re-dissolved in nuclease-
free water (GIBCO).   
Reverse transcription was performed in a 20 µL reaction. 2 µg of RNA obtained from 
Trizol extraction was first mixed with 1 µL of 500 μg/ml Oligo (dT)12-18 (NEB) and 1 µL 
of 10 mM dNTPs mix (promega), heated to 65 C and quickly chilled on ice. And then 4 
µL of 5X M-MLV Reverse transcriptase buffer and 1 µL of transcriptase (Promega) were 
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added and the reaction was initiated at 42 C for 80 min followed by inactivation at 70 C 
for 15 min.  
3.4.2 Semi-quantitative RT-PCR 
Of the 20 µl cDNA obtained, 1 to 2 µl was used for a semi-quantitative PCR with 
specific primers (Table 3.5). The PCR reaction mixture and the parameters for PCR were 
shown in Table 3.6. PCR products were then analyzed on 1.5 % agarose gel (1st Base).  












Primers Sequence (5' to 3') 
mFSHβ gene F GACAGCTGACTGCACAGGAC 
mFSHβ gene R GTTAGATAACCAACAGTATG 
mLHβ gene F GCCTGTCAACGCAACTCTGG 
mLHβ gene R CAGGCCATTGGTTGAGTCCT 
mGnRHR gene F CCACAGTGGTGGCATCAGGCCTTC 
mGnRHR gene R TAGCGTTCTCAGCCGAGCTCTTGG 
60s RP gene F ATGGTCCAGCGTTTGACATA 
60s RP gene R TTTCCCAACCTTCTTGGTGT 
ACTN4 RT F AGCAATCACATCAAGCTGTCG 
ACTN4 RT R CCACACTCATGATCCGGTTG 
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Components Volume (L) 
cDNA template  1˜2  
10 X Dynazyme buffer (Finnzyme) 2.5 
10 mM dNTPs 0.5 
Forward primer (10 μM) 2.5 
Reverse primer (10 μM) 2.5 
Dynazyme (2 U/μL,  Finnzyme) 0.5 
Nuclease-Free Water to final volume 25 
Step Cycle Temperature (C) Time 
1 1  95 3 min 






3 1 72 5 min 
4 1 4 ∞ 
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3.4.3 Quantitative real-time RT-PCR 
 Real-time PCR was performed using Power SYBR PCR master mix (Applied 
Biosystems) with an ABI PRISM 7000 Sequence Detection System instrument (Applied 
Biosystems). Primers for real-time PCR are the same as those listed in Table 3.5. The 
samples were first warmed to 50 °C for 2 min, and then heated to 95 °C for 10 min, 
followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Relative changes in mRNA 
levels were calculated using the ΔΔCt algorithm. Each value is representative of three 
replicates.   
3.5 Plasmid construction 
3.5.1 Expression plasmids 
The expression plasmids for full length and truncated ACTN4 were generated by PCR 
amplification and subsequently digested and ligated with the indicated vector. The 
corresponding primer sets and vectors for generating each expression plasmid were 
shown in Table 3.7. For insert PCR amplification, a 50 μL PCR reaction was set up as 
shown in Table 3.8. The produced insert(s) were then purified by PCR purification kit 
(Promega) and eluted in 50 μL H2O. 5 μL of insert and 0.5 μg of vector were mixed 
together in a 20 μl digestion system (Promega). After being digested with the individual 
restriction enzymes, whose site is carried by each primer, at 37 °C for 2 h, the mixture 
was purified by PCR purification kit, and finally eluted in 17 μl H2O. After adding the T4 
DNA ligation buffer and ligase (Promega), the mixture was incubated at 25 °C for 2 h. 5-
20 μL of resulting ligation product was used for transformation followed by PCR 
screening. Cacybp over-expression plasmid was generated as previously described 
(Ghosh, Yu et al. 2011). 
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    Forward primer sequence  (5' to 3') 

























Table 3.8 Components of PCR amplification of inserts for expression plasmids.   
Components Volume (L) 
cDNA template  5  
5 X GoTaq® Flexi buffer (Promega) 10 
PCR Nucleotide Mix (10 mM each) 1 
MgCl2 solution ( 25 mM)  4 
Forward primer (10 μM) 5.0 
Reverse primer (10 μM) 5.0 
GoTaq® polymerase (5 U/μL, Promega ) 0.25 




3.5.2  Luciferase vectors 
LHβ promoter was created by ligating 1300 bp of the proximal murine LHb gene 
promoter into pGL2 Basic vector (Promega) as described in (Feng, Lawson et al. 2008). 
FSHβ promoter was created by amplifying -1990 to +1 bp of FSHβ promoter gene from 
murine genomic DNA and inserted into pGL2 vector. 
3.5.3 Construction of siRNA constructs 
3.5.3.1 Design of oligonucleotides 
 The oligonucleotides for ACTN4 short hairpin RNA (shRNA) construct were designed 
based on the mRNA sequence. The target region for knocking down was determined by 
BLOCK-iT™ RNAi Designer (Invitrogen). Two pairs of oligos were synthesized to 
target ACTN4 as shown in Table 3.9. The underlined sequences indicate the shRNA 
targeting regions.  




Sequence (5’-3’) Forward  












3.5.3.2 Annealing of oligonuleotides 
The shRNA oligonucleotides were dissolved and diluted to a concentration of 3 µg/µL in 
nuclease-free H2O and the annealing reaction was set up by mixing 1 µL of each oligo 
with 48 µL annealing buffer (100 mM NaCl and 50 mM HEPES, pH 7.4). The annealing 
mixture was first heated to 90 °C for 4 min, and then was switched to 70 °C for 10 min, 
after which the reaction mixture was cooled down to 37 °C for 20 min, and finally was 
kept at 4 °C for 2 h. 
3.5.3.3 Restriction digestion of pSUPER vector 
The pSUPER Basic vector (Oligoengine) (1 µg) was linearized with HindIII and BglII.  
Digestion was performed at 37 °C. Enzymes were then inactivated at 65 °C for 15 min. 
The linearized vector was loaded on a 1.1 % agarose gel and purified using the Gel 
purification kit (Qiagen). 
3.5.3.4 Ligation of annealed oligos and linearized vector 
Ligation mixture was assembled as shown in Table 3.10, and the reaction was carried out 















3.5.4 Plasmid isolation and verification 
Plasmid DNA of selected colonies was isolated using Wizard Plus Miniprep Kit 
(Promega). The insert sequence of each construct was verified by DNA sequencing. 
Sequencing PCR was assembled and cycling parameters were listed in Table 3.11, using 
corresponding sequencing primers indicated by vector map. After sequencing PCR, the 
DNA was precipitated with 20 μL of 3 M NaOAc (pH 4.6) and 50 μL 95 % ethanol for 
30min at -20 °C, followed by centrifugation at 13,000 rpm  for 30 min at 4 °C. The DNA 





Annealed oligonucleotides 1 
Linearized pSUPER vector (0.3 μg/uL) 1 
10X T4 DNA ligase buffer  (Promega) 1 
T4 DNA ligase (3 U/µL, Promega) 1 
Nuclease-Free Water 6 
Total volume 10 
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Components Volume (L) 
DNA template  250-500 ng 
5X sequencing buffer ( Applied Biosystems) 2 
Primer (5 μM) 1 
Bigdye Version 3 (Applied Biosystems) 1 
Nuclease-Free Water to final volume 10 
Step Cycle Temperature (C) Time 





          4 min 
2 1 4 ∞ 
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3.6 Luciferase promoter analysis 
Cells were seeded in 24-well plates. After overnight plating, 500 ng/well of over-
expression/shRNA plasmids, 500 ng/well of the luciferase reporter plasmids and 25 
ng/well of simian virus 40 (SV40) were transient transfected into the cells and the cells 
were continued to culture for 48-72h. Cells were then rinsed with ice-cold PBS, and the 
luciferase activity was measured by using the Dual-Glo system (Promega) after splitting 
the cell lysate into 96well-white plate, in a Verita Microplate luminometer (Turner 
Biosystem). Luciferase activity was normalized to the levels of Renilla luciferase. The 
results were expressed as the fold change over basal levels, which were the values that 
were generated from transfection of the luciferase reporter plasmids with empty 
vector/shGFP. Statistical analysis was done by paired t-test. 
3.7 Western blot 
The protein sample preparation and quantitation were performed as described in 3.2. For 
each sample, 25 μg of protein was mixed with 2× SDS loading buffer and heated for 10 
min at 95 °C before loading on a 10-12 % SDS polyacrylamide gel (PAGE). Constant 
voltage at 80 V was set for the first 20 min, and followed by increasing to constant 
voltage at 130 V.  
The proteins were then transferred to an Immuno-Blot PVDF (Bio-Rad) membrane in the 
transfer buffer at a constant voltage of 80 V for 1 h at 4 °C. Once the transfer was 
completed, the membrane was taken out and incubated with a series of buffers (Table 
3.12). All the incubation and wash steps were performed on a rotating platform. The 
membrane was first blocked with the blocking buffer for 1 h at RT, followed by washing 
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three times in the washing buffer. And then it was incubated with the primary antibodies 
(Table 3.13) diluted in the antibody dilution buffer for 1 h at RT, or overnight at 4 
o
C.  
Subsequently, washing was carried out as described above. The membrane was then 
incubated with the appropriate secondary antibody diluted in the antibody dilution buffer 
for 1 h at RT. The membrane was then washed as described above and then incubated 
with the SuperSignal® WestPico Chemiluminescent substrate (Pierce) for 5 min. After 
rinsing in H2O for 5 sec, the membrane was placed in the middle of two transparent 
plastic sheets. Autoradiography was performed using X-ray film (Kodak Scientific 
Imaging Film X-OMAT
TM
) in an autoradiograph cassette. Exposure time was optimized 
from 10 sec until the demanded band was detected. The film was developed using a 
Kodak M35 X-OMAT Processor.  
Table 3.12 Buffers used in western blot. 
Buffers Component 
2 X loading buffer 100 mM Tris-HCl pH 6.8, 200 mM β-ME, 4 % SDS, 0.2 % 
Bromophenol blue, 20 % glycerol 
Running buffer 25 mM Tris-HCl pH 8.3, 192 mM glycine, 0.1 % SDS 
Transfer buffer 25 mM Tris-HCl pH 8.3, 192 mM glycine 
Washing buffer 
(TBST) 
10 mM Tris-HCl pH 8.0, 150 mM NaCl,  0.1 % Tween-20 
Blocking buffer TBST with 10 % non-fat milk 
Antibody dilution 
buffer 
TBST with 1 % non-fat milk 
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Table 3.13 Antibodies used in western blot and confocal microscopy. 




ACTN 4 Santacruz 
Biotechnology 
1: 1000 1:100 
Actin BD Transduction 
Laboratories 
1: 5000 NA 
NPM Sigma 1: 5000 NA 
FLAG Sigma 1: 2000 NA 
Cacybp Santacruz 
Biotechnology 
1: 5000 NA 
β-catenin Abcam 1: 1000 1:200 
GAPDH Santacruz 
Biotechnology 




p-GSK3 β Santacruz 
Biotechnology 
1:2000 NA 
Sf-1 Upstate 1:2000 NA 
Goat anti rabbit IgG HRP Santacruz 
Biotechnology 
1:5000 NA 
Bovine anti goat IgG HRP Santacruz 
Biotechnology 
1:5000 NA 
Rabbit anti mouse IgG HRP Santacruz 
Biotechnology 
1:5000 NA 
Alexa Fluor-546 conjugated 
donkey-anti goat IgG 
Invitrogen NA 1:200 
Alexa Fluor-594 conjugated 
goat-anti rabbit IgG 




3.8 Confocal microscopy 
Coverslips (VWR) were pre-cleaned and kept in 70 % ethanol. Just before coating, they 
were rinsed in 100 % ethanol, and dried. The coverslips were then sterilized by 
Ultraviolet (UV), and 0.1 % poly-L-Lysine (Sigma) solution was applied at 300 
µL/coverslip.  After incubation for 30 min, the solution was removed and the coverslips 
were dried and further sterilized with UV for 30 min. LβT2 cells were seeded on poly-L-
lysine (Sigma) coated sterilized coverslips in 6-well plates and starved in serum free 
medium overnight before treatment with GnRH (Sigma). After treated for the indicated 




), and then 
fixed in 3 % paraformaldehyde (PFA) (Sigma) at RT for 15 min followed by washing 
three times with 50 mM NH4Cl in DPBS. They were rinsed in DPBS and permeabilized 
with DPBS containing 0.5 % saponin (Sigma) at RT for 15min. After permeabilization, 
the fixed cells were blocked in DPBS containing horse serum (10 %) plus BSA (1 %) at 
RT for 1 h. Incubation with primary antibodies (Table 3.13) was carried out for 1 h at RT 
or overnight at 4 °C. The cells were washed 3 × 3 min in DPBS containing 0.1 % saponin, 
and incubated with the secondary antibodies (Table 3.13) for 1 h at RT, followed by 6 × 2 
min washing in DPBS containing 0.1 % saponin. The stained cells were then mounted 
with DAPI (4’6-diamidino-2-phenylindole)-contained mounting solution (Santacruz), and 
examined by a LSM510 confocal fluorescence microscope (Carl Zeiss). For fluorescence 
quantitation assays, the unit fluorescence in the nucleus (In) and the whole cell (Iw) were 
calculated as intensity/area. The results were shown as the fold change over mock-treated 
controls. A minimum of 50 cells (i.e., ±10 microscopic fields) in total were counted. 
Statistical analyses were performed by two-sample homoscedastic t-test.  
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3.9 Promoter pull-down assay 
3.9.1 Generating the mutated LHβ promoters 
The intact rat LHβ (rLHβ) promoter in CAT6 vector is a general gift given by A/P 
Melamed. There are two putative Sf-1 binding sites, which are located at the proximal 
region -59 bp and distal region -119 bp of the intact rLHβ promoter, respectively 
(Melamed, Kadir et al. 2006). The 3 mutated rLHβ promoters, which have no Sf-1 
binding sites or only one Sf-1 binding site, were generated by QuickChange
TM
 site-
directed mutagenesis kit (Stratagene) following the instruction using each pair of primers 
(Table 3.14). 







Sequence (5’-3’) Forward  



















(Mutated nucleotides were underlined.)  
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3.9.2 Generating the biotin-labeled intact and mutated LHβ promoters 
The biotin-labeled promoters were generated by PCR amplification. In each PCR reaction, 
each of the promoters generated in 3.9.1 was used as a template, and biotin-labeled 
promoter was amplified using 5’-biotin-labeled forward primer (5’-
GCTGGTCCCTGGCTTTTCTG-3’), which starts from the -145 bp relative to the 
transcription start site 0 bp, and the normal reverse primer (5’-
ACCTTCCCTACCTTGGGCAC-3’), which starts from the transcription start site; the 
control non-biotin-labeled promoters was amplified using the same forward primer but 
without 5’ biotin-labeling, and the normal reverse primer. The PCR reaction was carried 
out in a 50 µL reaction, with 100 ng of each template, the composition of the reaction 
was previously shown in Table 3.8. The mixture was first denatured at 95 °C for 2 min, 
followed by 35 cycles of 95 °C for 30 sec, 59 °C for 1 min, and 72 °C for 20 sec, and 
finally extended at 72 °C for 5 min. 
3.9.3 Promoter pull-down assay 
For each reaction, 500 µg of nuclear extract was mixed with 50 µL of the biotin-labeled 
promoter alone or together with competitive non-biotin-labeled promoter, and incubated 
overnight at 4 °C with gentle rotation. On the next day, 20 µL of streptavidin beads was 
then added and incubated with the mixture for another 4 h at 4 °C with gentle rotation. 
The protein-promoter-bead complex was then washed 3 times in TBST buffer and was 
eluted by 2× reduced SDS loading buffer and applied to western blot analysis. The non-
biotin-labeled promoter alone mixed with nuclear extraction was used as a binding 
control.  
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Chapter 4. ICAT proteomic 
profiling of the protein responses 
induced by GnRH in gonadotrope 
cell line   
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4.1 Introduction 
GnRH is the central regulator of the reproductive system through stimulating the 
synthesis and secretion of gonadotropins LH and FSH from pituitary (Tsai 2006). GnRH 
activates multiple downstream signaling through binding to the type I GnRH receptor, 
and subsequently transmitting the signals via the heterotrimeric Gq protein and inducing 
the elevation of intracellular Ca
2+
 level, activation of PKC/MAPK signaling cascades, 
which then promoting gonadotropins transcription and secretion (Reiss, Llevi et al. 1997). 
GnRH agonist (GnRHa) analogs have been used to treat steroid-dependent diseases 
(Schultze-Mosgau, Griesinger et al. 2005) and proved to be a safe and efficient class of 
drugs. As the important clinical applications of GnRHa, the signal transduction pathways 
of GnRH, therefore, are of great interests to be identified. However, MAPK cascades are 
the only well studied and characterized pathways so far (Reiss, Llevi et al. 1997; Harris, 
Bonfil et al. 2002; Harris, Chuderland et al. 2003; Bonfil, Chuderland et al. 2004; Naor 
2009). Recent studies suggested Wnt signaling may also involve in mediating GnRH 
response (Gardner, Maudsley et al. 2007; Salisbury, Binder et al. 2008; Gardner and 
Pawson 2009; Gardner, Stavrou et al. 2010), and most findings were focused on β-
catenin, which is known to be the key effecter of canonical Wnt signalling.  
It is well known that in the Wnt/canonical pathway β-catenin is activated by Wnt ligand 
through acting on a destruction complex, composed of casein kinase I (CKI) and 
glycogen synthase kinase-3β (GSK-3β) (Huelsken and Behrens 2002). The activated β-
catenin then functions as a coactivator with the transcription factors T-cell factor (TCF)/ 
lymphoid enhancer factor (LEF) in mediating the transcription of Wnt target genes such 
as c-Myc, c-Jun, Fra-1, and others (Moon, Kohn et al. 2004; Nelson and Nusse 2004). 
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Recent studies indicated that β-catenin and the TCF target gene c-Jun are likely involved 
in mediating GnRH induced LHβ gene transcription (Salisbury, Binder et al. 2007; 
Salisbury, Binder et al. 2009). Although these results highlighted the possibility of 
crosstalk between Wnt signalling and GnRH signalling in the field of gonadotrope 
biology, the knowledge however is only limited to a few mediators, which is hard for the 
elucidation of a full spectrum of the signalling pathway.  
Previous signaling pathway studies in gonadotrope were mostly performed at the 
transcriptomic level, such as extensive microarray studies of 1 to 6 h of GnRH treatment 
time course done by Sealfon’s group (Wurmbach, Yuen et al. 2001; Ruf, Fink et al. 2003; 
Ruf and Sealfon 2004), a similar microarray study of 1 h and 24 h of GnRH treatment 
done by Shawn’s group (Kakar, Winters et al. 2003), and a microarray analysis of  GnRH 
pulse frequency treatment done by Lawson’s group (Lawson, Tsutsumi et al. 2007). The 
results obtained from these transcriptomic studies turned out to advance the 
understanding of GnRH-induced MAPK pathways. However, so far no high-throughput 
proteomics study has been carried out to study the GnRH signaling. In order to address 
the research gap, we carried out cICAT-based proteomics experiment to identify 
differentially expressed proteins between mock-treated and GnRH-treated LβT2 cells. 
cICAT labeling, which only targets cysteine residues (Gygi, Rist et al. 1999; Hansen, 
Schmitt-Ulms et al. 2003; Li, Steen et al. 2003), greatly simplifies the MS of peptide 
mixture and may thereby facilitating the identification of low abundant proteins such as 
signaling molecules. 
Our study identified a number of gene products regulated by GnRH while involve in post 
translation modifications (PTMs), furthermore we found some of these proteins are 
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potential mediators of GnRH response through Wnt/ β-catenin signaling. On the basis of 
our data, we proposed novel signaling pathways, which advance the knowledge of 
crosstalk between Wnt signaling and GnRH signaling in the field of gonadotrope biology. 
4.2 Results 
4.2.1 cICAT proteomic profiling of whole cell lysate from mock-treated and 
GnRH-treated LβT2 cells. 
Total protein expression profiles of 4 h mock-treated and GnRH-treated LβT2 cells were 
analyzed by cICAT-based proteomics experiments. Three independent experiments were 
conducted as biological replicates. After treatment, total proteins were isolated from 
individual samples and subjected to cICAT labeling. The details of the sample 
preparation were described in chapter 3, and the flow chart of cICAT experiments is 




Figure 4.1 Schematic representation of the workflow of the cICAT–based proteomic 
profiling 
cICAT labeling were carried out in triplicates of whole cell lysate from mock-treated and 
GnRH-treated LβT2 cells. Mock-treated total protein extracts were labeled with light 
cICAT reagent-
12






The minimum ion score C.I. % was set as the value to which no more than 5% FDR was 
achieved. Based on this cut-off threshold, all the proteins identified from the random 
database search were single-peptide matches. With this filter, a total of 364 proteins from 
triplicate 1, 866 proteins from triplicate 2, and 797 proteins from triplicate 3 were 
confidently identified by matching MS/MS data to the protein sequences by MASCOT 
database search. A total of 307 unique proteins were commonly identified from at least 
two of the three independent experiments (Supplementary soft copy). The cellular 
distributions of the 307 proteins were analyzed by Ingenuity Pathway Analysis server 
(Figure 4.2). The result showed that about 26 % of proteins were from nucleus, 22 % of 
proteins were from cytoplasm, 14 % of proteins were from plasma membrane, 13 % of 
proteins were from mitochondria, 10 % of proteins were from cytoskeleton, 9 % of 
proteins were from extracellular, 4 % of proteins were from ribosome and 2% of proteins 
remained unknown.  
The ratios of differentially expressed proteins between mock-treated and GnRH-treated 
cells were calculated by GPS Explorer
TM
 software (Ver. 3.6). Each ratio was obtained by 
normalizing against median ratio of all the cICAT peptides detected in one sample. The 
ratios were then calculated by comparison of the clustered heavy-cICAT labeled peptides 
with light-cICAT labeled peptides, and the cut-off was fixed at 1.3 for up-regulation and 
0.77 for down-regulation. Applying these cut-off ratios to the three sets of biological 
triplicates, those common proteins which meet the criteria in at least two sets of the 
biological triplicates were selected as the significantly altered proteins. Here we 
identified 194 proteins as significantly altered proteins. As most of these proteins (93.8 %) 
were present twice in three experiments, the correlation of the protein ratios in two 
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datasets was plotted. For those proteins present in all three experiments, only the two 
most closed ratios were selected for correlation study (Figure 4.3). 
 
Figure 4.2 Cellular distribution of all the unique proteins identified by cICAT 
proteomics profiling.  
 
Figure 4.3 Correlation between the cICAT ratios of the significantly altered proteins 
by GnRH-treatment from two independent datasets. 
The correlation of the cICAT ratios of the 194 significantly altered proteins from 2 
datasets were determined by using the Log10 value of each ratio. The correlation 
coefficiency (R
2




4.2.2 Gene Oncology studies of the significantly altered proteins  
Gene ontology studies using DAVID were carried out for the significantly altered 
proteins by GnRH-induction. GO distributions in molecular function were classified and 
demonstrated in Figure 4.4. Surprisingly, phosphoprotein and acetylation were found as 
the top 2-ranked functions comprising the most number of significantly altered proteins 
induced by GnRH. These two functions are closely correlated to our research topic--
regulation of gonadotropins. The corresponding proteins list involved in phosphorylation 
were shown in Table 4.1, and the proteins involved in acetylation were shown in Table 
4.2. 
 
Figure 4.4 GO analysis of significantly regulated proteins by GnRH-induction. 
GO analysis were done using DAVID software, the percentiles of genes involved in each 
molecular function were plotted against the corresponding molecular function (bar). The -
Log10 P-value of each molecular function was also indicated in the graph (line). Only the 
molecular functions with P <0.05 were shown in this graph. 
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Table 4.1 Significantly altered proteins which are involve in phosphorylation. 
 (↑ refers to up-regulation; ↓ refers to down-regulation; Sp1, Sp2, Sp3 refers to each of 




Avg ICAT Ratio (H/L) Exp 
Pat. Sp1 Sp2 Sp3 
IPI00136929 Actg1 Gamma actin-like protein 879.14   1.46 ↑ 
IPI00648173 Cltc Clathrin, heavy polypeptide 1.38   1.56 ↑ 
IPI00323064 Pdcd4 Programmed cell death 
protein 4 6101.59 7184.27   
↑ 
IPI00667859 Gm6438 similar to Ribosomal 
protein S27a   1512.09 2906.32 
↑ 
IPI00828704 Btk Bruton agammaglobulinemia 
tyrosine kinase   767.39 1083.46 
↑ 
IPI00830276 Adcy10 Isoform 2 of Adenylate 
cyclase type 10 2414.80 46.86   
↑ 
IPI00757256 Myo16 Isoform 2 of Myosin-
XVI   15.89 517.92 
↑ 
IPI00459500 Obscn obscurin isoform 1 554.06 10.90   ↑ 
IPI00650012 
Dnajc7 DnaJ (Hsp40) homolog, 
subfamily C, member 7 
(Fragment) 
  1.78 1.51 ↑ 
IPI00230044 Tpm3 Isoform 2 of Tropomyosin 
alpha-3 chain   1.71 2.54 
↑ 
IPI00405364 
Ddx17 Isoform 2 of Probable 
ATP-dependent RNA helicase 
DDX17 
  1.60 1.58 ↑ 
IPI00224109 Hsph1 Isoform HSP105-beta of 
Heat shock protein 105 kDa   1.54 2.26 
↑ 
IPI00658779 Gm6563 hypothetical protein 
isoform 2   1.50 1.50 
↑ 
IPI00663627 Flnb Filamin-B 20.17 1.35 1.27 ↑ 
IPI00115650 Cacybp Calcyclin-binding 
protein 0.67 0.82 0.65 
↓ 
IPI00621229 Rps8-ps1 Ribosomal protein S8 0.74 0.81 0.76 ↓ 
95 
IPI00123494 Psmd2 26S proteasome non-
ATPase regulatory subunit 2 0.71 0.79 0.57 
↓ 
IPI00117016 Mcm4 DNA replication 
licensing factor MCM4   0.76 0.76 
↓ 
IPI00130173 Uba2 SUMO-activating enzyme 
subunit 2 0.00 0.75 0.79 
↓ 
IPI00874963 Gpbp1l1 Vasculin-like protein 1 0.57 0.74   ↓ 
IPI00112555 Gars Glycyl-tRNA synthetase 0.66 0.73 0.60 ↓ 
IPI00886245 Gdi1 Guanosine diphosphate 
(GDP) dissociation inhibitor 1   0.73 0.64 
↓ 
IPI00116310 Dnahc2 Putative uncharacterized 
protein Dnahc2 0.67 0.71   
↓ 
IPI00653598 
Uqcrc1 cytochrome b-c1 
complex subunit 1, 
mitochondrial precursor 
0.67 0.70 0.63 ↓ 
IPI00130491 Prkch Protein kinase C eta type   0.69 0.56 ↓ 
IPI00321446 Prkca Protein kinase C alpha 
type   0.69 0.60 
↓ 
IPI00321647 Eif3c Eukaryotic translation 
initiation factor 3 subunit C   0.68 0.58 
↓ 
IPI00126898 Scn11a Sodium channel protein 
type 11 subunit alpha   0.66 0.00 
↓ 
IPI00125091 Lasp1 LIM and SH3 domain 
protein 1   0.65 0.67 
↓ 
IPI00223757 Akr1b3 Aldose reductase   0.65 0.67 ↓ 
IPI00649191 Psme3 Proteaseome (Prosome, 
macropain) 28 subunit, 3   0.64 0.68 
↓ 
IPI00849793 Rpl12 60S ribosomal protein 
L12 0.40 0.53 0.21 
↓ 
IPI00399702 Phf6 Isoform 2 of PHD finger 
protein 6 0.71 0.45 0.74 
↓ 
IPI00131376 Spnb1 spectrin beta chain, 
erythrocyte   0.23 0.47 
↓ 
IPI00409393 Ltbp1 Putative uncharacterized 
protein Ltbp1 0.00 0.00 0.00 
↓ 
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IPI00349296 Tanc1 Isoform 1 of Protein 
TANC1   0.00 0.00 
↓ 
IPI00122486 Camkv CaM kinase-like vesicle-
associated protein   0.00 0.00 
↓ 
IPI00378681 Ubr4 Isoform 1 of E3 ubiquitin-
protein ligase UBR4   0.00 0.00 
↓ 
IPI00608114 Mycbp2 probable E3 ubiquitin-
protein ligase MYCBP2 0.00 0.00 0.00 
↓ 
IPI00648094 Tk1 Thymidine kinase, cytosolic 0.00 0.00 0.00 ↓ 
IPI00857004 Chd4 50 kDa protein 0.00 0.00 0.00 ↓ 
IPI00944011 
Ripk3 receptor-interacting 
serine/threonine-protein kinase 3 
isoform 2 
0.00 0.00 0.00 ↓ 
IPI00127176 6720456B07Rik Probable 
protein BRICK1   0.00 0.00 
↓ 
IPI00127449 Zfp622 Zinc finger protein 622   0.00 0.00 ↓ 
IPI00130218 Kif11 Kinesin-like protein 
KIF11   0.00 0.00 
↓ 
IPI00230680 Atp4a Potassium-transporting 
ATPase alpha chain 1   0.00 0.00 
↓ 
IPI00408595 
Wnk2 Isoform 2 of 
Serine/threonine-protein kinase 
WNK2 
  0.00 0.00 ↓ 
IPI00421063 Brca1 breast cancer type 1 
susceptibility protein homolog   0.00 0.00 
↓ 
IPI00649450 Gstm1 23 kDa protein   0.00 0.00 ↓ 
IPI00653178 1190007F08Rik Putative 
uncharacterized protein   0.00 0.00 
↓ 
IPI00666451 
Trpm1 Isoform 2 of Transient 
receptor potential cation channel 
subfamily M 
  0.00 0.00 ↓ 
IPI00762214 Trrap 434 kDa protein   0.00 0.00 ↓ 
IPI00556723 Dnm1l Isoform 1 of Dynamin-1-
like protein   0.00 0.43 
↓ 
IPI00119876 Dync1h1 Cytoplasmic dynein 1 
heavy chain 1   0.00 0.57 
↓ 
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IPI00272622 Metap1 Methionine 
aminopeptidase 1 0.00 0.00   
↓ 
IPI00605122 Btbd7 Isoform 3 of BTB/POZ 
domain-containing protein 7 0.00 0.00   
↓ 
IPI00113348 Fam59a Isoform 1 of Protein 
FAM59A 0.00   0.00 
↓ 
IPI00124178 Sptlc2 Serine 
palmitoyltransferase 2 0.00   0.00 
↓ 
IPI00229217 Mapk15 Mitogen-activated 
protein kinase 15 0.00   0.00 
↓ 
IPI00308198 Ubxn2b UBX domain-containing 
protein 2B 0.00   0.00 
↓ 
IPI00347275 Vps24 Charged multivesicular 
body protein 3 0.00   0.00 
↓ 
IPI00410869 
Lrp8 Low density lipoprotein 
receptor-related protein 8, 
apolipoprotein e receptor 





0.00   0.00 ↓ 
IPI00480458 Itgb4 Isoform 3 of Integrin beta-
4 0.00   0.00 
↓ 
IPI00605176 Trio Isoform 2 of Triple 
functional domain protein 0.00   0.00 
↓ 
IPI00649093 Myo18a Myosin XVIIIa 0.00   0.00 ↓ 
IPI00742341 Nalcn sodium leak channel non-
selective protein 0.00   0.00 
↓ 
IPI00918828 Plxna2 Protein 0.00   0.00 ↓ 
IPI00850539 LOC100044138 similar to 
CDCrel-1AI isoform 1 0.50   0.54 
↓ 
IPI00420835 Itga6 Isoform Alpha-6X1B of 
Integrin alpha-6 0.00   0.61 
↓ 
IPI00828969 Pdlim5 Isoform 1 of PDZ and 




phosphatase 2A catalytic subunit 
alpha iso 
0.40   0.77 ↓ 
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Table 4.2 Significantly altered proteins which are involve in acetylation. 
 (↑ refers to up-regulation; ↓ refers to down-regulation; Sp1, Sp2, Sp3 refers to each of 




Avg ICAT Ratio (H/L) 
Exp 
Pat. Sp1 Sp2 Sp3 
IPI00875110 Idh2 52 kDa protein   16421.24 10936.26 ↑ 
IPI00667859 Gm6438 similar to Ribosomal 






  767.39 1083.46 ↑ 
IPI00230044 Tpm3 Isoform 2 of 
Tropomyosin alpha-3 chain   1.71 2.54 
↑ 
IPI00648173 Cltc Clathrin, heavy polypeptide 1.38   1.56 ↑ 
IPI00650012 
Dnajc7 DnaJ (Hsp40) homolog, 
subfamily C, member 7 
(Fragment) 
  1.78 1.51 ↑ 
IPI00658779 Gm6563 hypothetical protein 
isoform 2   1.50 1.50 
↑ 
IPI00136929 Actg1 Gamma actin-like protein 879.14   1.46 ↑ 
IPI00663627 Flnb Filamin-B 20.17 1.35 1.27 ↑ 
IPI00885495 Cmc1 COX assembly 
mitochondrial protein homolog 6639.63 76.47   
↑ 
IPI00130173 
Uba2 SUMO-activating enzyme 





phosphatase 2A catalytic 
subunit alpha iso 
0.40   0.77 ↓ 
IPI00828969 Pdlim5 Isoform 1 of PDZ and 
LIM domain protein 5 0.00   0.76 
↓ 
IPI00117016 Mcm4 DNA replication 
licensing factor MCM4   0.76 0.76 
↓ 
IPI00403706 Rnpep aminopeptidase B 
isoform 2   0.76 0.72 
↓ 
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IPI00309398 Mcm5 DNA replication 
licensing factor MCM5   0.71 0.71 
↓ 
IPI00128699 
Snrpn Small nuclear 
ribonucleoprotein-associated 
protein N 
0.57 0.62 0.70 ↓ 
IPI00649191 Psme3 Proteaseome (Prosome, 
macropain) 28 subunit, 3   0.64 0.68 
↓ 
IPI00125091 Lasp1 LIM and SH3 domain 
protein 1   0.65 0.67 
↓ 
IPI00223757 Akr1b3 Aldose reductase   0.65 0.67 ↓ 
IPI00115650 Cacybp Calcyclin-binding 
protein 0.67 0.82 0.65 
↓ 
IPI00310220 Gnb4 Guanine nucleotide-
binding protein subunit beta-4 0.62 0.77 0.64 
↓ 
IPI00653598 
Uqcrc1 cytochrome b-c1 
complex subunit 1, 
mitochondrial precursor 
0.67 0.70 0.63 ↓ 
IPI00321446 Prkca Protein kinase C alpha 
type   0.69 0.60 
↓ 
IPI00112555 Gars Glycyl-tRNA synthetase 0.66 0.73 0.60 ↓ 
IPI00321647 Eif3c Eukaryotic translation 
initiation factor 3 subunit C   0.68 0.58 
↓ 
IPI00649986 Psme2 proteasome activator 
complex subunit 2 isoform 2 0.42 0.56 0.58 
↓ 
IPI00123494 Psmd2 26S proteasome non-
ATPase regulatory subunit 2 0.71 0.79 0.57 
↓ 
IPI00119876 Dync1h1 Cytoplasmic dynein 1 
heavy chain 1   0.00 0.57 
↓ 
IPI00649328 Cisd3 Cisd3 protein 0.72 0.84 0.55 ↓ 
IPI00113849 
Cdc42 Isoform 2 of Cell 
division control protein 42 
homolog 
  0.64 0.53 ↓ 
IPI00556723 Dnm1l Isoform 1 of Dynamin-
1-like protein   0.00 0.43 
↓ 
IPI00849793 Rpl12 60S ribosomal protein 
L12 0.40 0.53 0.21 
↓ 
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IPI00378681 Ubr4 Isoform 1 of E3 ubiquitin-
protein ligase UBR4   0.00 0.00 
↓ 
IPI00453769 Cops7b COP9 signalosome 
complex subunit 7b   0.00 0.00 
↓ 
IPI00127176 6720456B07Rik Probable 
protein BRICK1   0.00 0.00 
↓ 
IPI00762214 Trrap 434 kDa protein   0.00 0.00 ↓ 
IPI00857004 Chd4 50 kDa protein 0.00 0.00 0.00 ↓ 
IPI00608114 Mycbp2 probable E3 ubiquitin-
protein ligase MYCBP2 0.00 0.00 0.00 
↓ 
IPI00130218 Kif11 Kinesin-like protein 
KIF11   0.00 0.00 
↓ 
IPI00136012 Ggcx Vitamin K-dependent 
gamma-carboxylase 0.00 0.00 0.00 
↓ 
IPI00409255 
D030016E14Rik Isoform 1 of 
UPF0636 protein C4orf41 
homolog 
0.00   0.00 ↓ 
IPI00318464 Eif1b Eukaryotic translation 
initiation factor 1b   0.00 0.00 
↓ 
IPI00272622 Metap1 Methionine 




Protein phosphorylation is one of the PTMs which is caused by the changing in metabolic 
activity, environmental conditions and hormonal signals (Karin 1994). Phosphorylation 
of transcription factors (TFs) modulate their transactivation activities through affecting 
the DNA-binding activity, the transcriptional activity and the subcellular localization of 
the TFs (Hunter and Karin 1992). In addition, phosphorylation has been found to be 
required for the signal transduction from cell surface to the nucleus in many cell contexts 
as well as GnRH-induced MAPK cascades in gonadotrope cells, reviewed by (Naor 
2009). Acetylation is another crucial PTM process that plays a key role in regulating gene 
expression. It is widely presented in chromatin proteins (Choudhary, Kumar et al. 2009). 
Except for regulating histone, acetylation is also implicated in the regulation of 
transcription factors, effecter proteins, molecular chaperons, and cytoskeleton proteins. 
Recent study even suggested that acetylation may crosstalk with other PTMs, including 
phosphorylation, methylation, ubiquitination, sumoylation for dynamic control of cellular 
signaling (Yang and Seto 2008). The studies in gonadotrope cell line also indicated that 
GnRH may regulate gonadotropin through modulating acetylation process, reviewed by 
(Melamed, Kadir et al. 2006). As both phosphorylation and acetylation are likely 
involved in regulating GnRH signaling, we therefore continue to investigate the potential 
pathways which may be modulated by these two regulatory processes. We utilized 
STRING software to analyze the protein-protein networks, which may help to discover 
the underlying mechanism. Under the “action mode”, we found both Cacybp and Ddx17 
act on β-catenin.  As β-catenin is a key effecter of the Wnt signaling, and GnRH was 
recently found to target Wnt signaling, we further looked for other potential factors which 
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may be involved in Wnt signaling through literature mining. Finally, we identified a 
group of proteins which may be potentially involved in this process (Figure 4.5). 
 
Figure 4.5 Predicted Wnt signaling players among the significantly altered proteins. 
The actions of Cacybp and Ddx17 on β-catenin were identified by STRING under “action 






Ppp2ca was down-regulated by GnRH treatment. Ppp2ca is the catalytic subunit of PP2A 
kinase (Janssens and Goris 2001), which was suggested to be essential for both GSK-3β-
dependent (Ivaska, Nissinen et al. 2002; Hildesheim, Belova et al. 2003; Lee, Seo et al. 
2005; Mitra, Menezes et al. 2012), and GSK-3β-independent degradation of β-catenin 
(Zhang, Yang et al. 2009). Ddx17 was found to be up-regulated by GnRH treatment. 
Ddx17 was previously found to act as a coactivator of β-catenin through forming a 
complex with β-catenin in the nucleus and subsequently promoting the β-catenin target 
gene expression (Shin, Rossow et al. 2007). Cacybp was found to be down-regulated by 
GnRH. It is known to be one of the component of E3 ligase complex which regulates the 
degradation of β-catenin through  GSK-3β independent mechanisms (Filipek 2006). 
Recently, Cacybp was also identified as a novel phosphatase which modulates ERK 1/2 
activity (Kilanczyk, Filipek et al. 2009; Kilanczyk, Filipek et al. 2011). Prkca was down-
regulated by GnRH-treatment. It was previously reported to function as a negative 
regulator of Wnt/ β-catenin signaling pathway, which phosphorylated N-terminal Ser/Thr 
residues of β-catenin and subsequently induced its degradation (Gwak, Cho et al. 2006; 
Gwak, Jung et al. 2009). All the above findings suggest that these significant altered 
proteins may play crucial roles in mediating crosstalk between Wnt signalling and GnRH 
signalling in the field of gonadotrope biology. 
4.2.3 Validation of ICAT identification by Western blot 
Among all the significantly altered protein, Cacybp was selected for downstream 
validation. The expression levels of Cacybp in biological triplicates were validated by 
western blot analysis. As shown in Figure 4.6, the expression level of Cacybp was down-
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regulated by GnRH in all the biological replicates. The result is consistent with our ICAT 
identification.  
 
Figure 4.6 Validation of ICAT identification on selected proteins. 
Western blot studies were conducted to show the Cacybp and β-catenin expression levels 




4.2.4 Investigation of intracellular expression of β-catenin upon GnRH-induction 
Although β-catenin is the focus point of Wnt signaling, we, however, were not able to 
detect it in ICAT profiling. We therefore used other methods to investigate the 
intracellular expression of β-catenin.  First, we used western blot analysis to compare the 
overall expression levels of β-catenin in 4 h mock-treated and GnRH-treated LβT2 cells, 
and observed an increase of the expression level of β-catenin upon treatment in two of the 
biological triplicates (Figure 4.6). Next we did immunofluorescence experiment to check 
the cellular distribution of β-catenin in 4 h mock-treated and GnRH-treated LβT2 cells 
(Figure 4.7), and showed that the protein level of β-catenin in the whole cell was 
significantly increased after GnRH-treatment, which is consistent with the western blot 
result. However, the increasing amount of β-catenin was mostly present in the cytoplasm. 
While there might be slight increase of β-catenin level in the nucleus, a more precise 






Figure 4.7 Immunofluorescence analysis for intracellular distribution of β-catenin 
after 4 h GnRH-induction in LβT2 cells. 
LβT2 cells were seeded on pre-coated coverslips and serum starved for 12 h, and were 
exposed to 100 nM GnRH or mock for 4 h. Cells were fixed and then stained for β-
catenin (red) and nuclei with DAPI (blue). Scale bar=10 µm. 
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4.2.5 Investigation of mechanisms mediating GnRH regulation on β-catenin 
As we have found that β-catenin expression level is elevated by GnRH induction, we next 
investigate which mechanism mediates the GnRH regulation on β-catenin. So far it has 
been known that the activity of β-catenin can be regulated through two ubiquitination 
pathways, each of which is composed of different E3 ligase complexes (Logan and Nusse 
2004; Fukushima, Zapata et al. 2006). The best characterized one was GSK-3β-dependent 
degradation of β-catenin (Kitagawa, Hatakeyama et al. 1999; Latres, Chiaur et al. 1999; 
Liu, Kato et al. 1999; Winston, Strack et al. 1999). GSK-3β  is a well-known negative 
regulator of Wnt signaling. The phosphorylation of GSK-3β at Ser 9 induced by Wnt 
ligand activation has been suggested to result in the inhibition of GSK-3β activity, thus 
rescue β-catenin from degradation (Gardner, Maudsley et al. 2007). Hence we thought to 
check whether the phosphorylation status of GSK-3β is also regulated by GnRH. We 
treated LβT2 cells with mock or GnRH for 30 min, 2 h, and 4 h respectively, extracted 
the total proteins (described in Chapter 3) from each treatment, and then conducted 
western blot to detect both the GSK-3β and p-GSK-3β (Ser 9) proteins. As shown in 
Figure 4.8, we found that the expression level of Ser 9 phosphorylated GSK-3β showed 
not much difference in the 30 min GnRH-treated cells compared to the mock-treated 
control, while we did see the difference in the 4 h treatment group that upon 4 h GnRH-
treatment the abundance of p-GSK-3β was increased compared to the 4 h mock-treated 
control. However interestingly, the relative abundance of p-GSK-3β in 4 h GnRH-treated 
cells was reduced compared to 30 min GnRH-treated cells, and the phenomenon was the 
same for the mock-treated controls, given that there are no abundance changes for total 
GSK-3β proteins. The finding indicates that GSK 3β-dependent pathway, through 
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modulating the phosphorylation at Ser 9, may not be the only pathway mediating GnRH 
effect on β-catenin in LβT2 cells.  
 
Figure 4.8 Western blot analysis of GnRH-induced Ser9 phosphorylation of GSK-3β 
in LβT2 cells. 
LβT2 cells were treated with mock or GnRH for 30 min and 4 h respectively and the total 
proteins from each treatment were extracted and applied for western blot analysis.  Both 




Modulation of gonadotrope cell signaling by GnRH and its analogs has great application 
potential in the therapeutic field for treating the diseases such as infertility and gonadal 
hormone dependant tumors. However, so far, most knowledge of GnRH-induced 
regulation is at the transcriptional level, and the most well studied signaling pathway 
involved is MAPK signaling. To expand the current knowledge, we carried out this 
proteomics study. Since our initial aim is to identify regulatory proteins, which are 
mainly transcription factors and kinases and known to be low abundance proteins (Gygi, 
Rochon et al. 1999), we used the cICAT-based labeling technology. The top-ranked two 
molecular functions, which were identified by cICAT, were shown as  phosphorylation 
and acetylation (Figure 4.3). Phosphorylation was known to be difficult to analyze by 
proteomic methods due to the small proportion of phosphorylated proteins among the 
whole protein complex. Our study demonstrated the effectiveness of the cICAT approach 
for detecting the low abundance proteins.   
As mentioned just now, phosphorylation and acetylation are identified as two major 
molecular functions among all the GnRH-induced proteins. Acetylation is a crucial PTM 
process in regulation of histone, transcription factors, effecter proteins, molecular 
chaperons, and cytoskeleton proteins (Choudhary, Kumar et al. 2009). Although not 
many studies have been carried out in this field, acetylation has been implicated to be 
involved in the regulation of gonadotropins. It has been reported that upon GnRH 
induction, lysine residues of histone H3, H4 at the LHβ gene locus became acetylated 
(Melamed, Kadir et al. 2006), possibly through the active recruitment of histone acetyl 
transferases (HATs). The HAT, p300, was found to bind with LHβ gene promoter, and 
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the binding was enhanced by GnRH induction (Mouillet, Sonnenberg-Hirche et al. 2004). 
In addition, several transcription factors such as Sf-1, SRC-1, SRC-2, which activate LHβ 
and FSHβ in gonadotrope, were found to interact with HATs in other cell contexts (Jacob, 
Lund et al. 2001; Lund, Borud et al. 2002). GnRH-induced acetylation may become a 
new research area to explore in the future.  
In this study, phosphorylation is identified as the top-ranked molecular function, which 
involves the most number of significantly altered proteins by GnRH induction. 
Phosphorylation and dephosphorylation of transcriptional factors and kinases have been 
widely reported in GnRH-induced MPAK pathways (Harris, Bonfil et al. 2002; Harris, 
Chuderland et al. 2003; Kraus, Benard et al. 2003; Lopez-Bergami and Ronai 2008), 
while in our study we found that several proteins involved in phosphorylation are also 
likely to regulate β-catenin, a crucial Wnt signaling effecter, as well as other mediators in 
Wnt signaling. The involvement of Wnt signaling in mediating the GnRH response was 
first published by Gardner’s group, who found that β-catenin is a critical effecter 
mediating the GnRH induced production of LHβ gene (Salisbury, Binder et al. 2007), and 
possibly other gonadotropin genes (Salisbury, Binder et al. 2008). GnRH was also found 
to stimulate several known TCF target gens including Jun, Fra1, and Myc (Wurmbach, 
Yuen et al. 2001; Yuen, Wurmbach et al. 2002; Nateri, Spencer-Dene et al. 2005; 
Kikuchi, Kishida et al. 2006). However, how the GnRH signaling modulates the activity 
of β-catenin is not clear.  
Here comes to the question: how the GnRH signal is transduced to β-catenin and 
TCF/LEF-dependent genes in gonadotrope cells? In the canonical Wnt signaling, 
regulation of β-catenin is always linked to a well-known GSk-3β dependent pathway, in 
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which a GSK-3β containing inhibition complex modulates the phosphorylation and 
degradation of β-catenin (Gordon and Nusse 2006; Kikuchi, Kishida et al. 2006).  
However in LβT2 cells, we observed increased expression level of β-catenin induced by 
GnRH but seems not through phosphor-inhibition of GSK-3β at Ser 9. Thus we conclude 
that in gonadotrope cells, GnRH regulation of β-catenin may not be through inhibiting 
GSK-3β, or through inhibiting GSK-3β but in a manner, independent of Ser 9 
phosphorylation. Other than the GSk-3β-dependent pathway, the stability of β-catenin 
can be modulated by GSk-3β-independent mechanism. In this pathway, β-catenin 
degradation can be mediated by direct interaction with an ubiquitin ligase complex. 
Cacybp, which was found to be down-regulated by GnRH, is just one component of E3 
ubiquitin ligase complex (Filipek 2006). Unlike the GSK-3β inhibition complex, Cacybp 
inhibition complex controls the degradation of β-catenin not through phosphorylation 
(Filipek 2006; Fukushima, Zapata et al. 2006). Furthermore, Cacybp/SIP was found as a 
novel phosphatase, which has the ability to dephosphorylate ERK1/2 (Kilanczyk, Filipek 
et al. 2011). As ERK phosphorylation is required for the activation of gonadotropin 
responsive genes, such as Nur77 (Bliss, Navratil et al. 2012), the down-regulation of 
Cacybp may also facilitate the expression of  gonadotropin responsive genes. While the 
mechanisms of Cacybp regulation by GnRH is not clear, recent evidence indicated that it 
is likely regulated through GnRH-induced Ca
2+
 signalling pathway (Liang, Luo et al. 
2007). Ddx17 and its homologous protein Ddx5 were reported to be transcriptional 
coactivators of several key transcriptional factors (Janknecht 2010; Fuller-Pace and 
Moore 2011). Ddx17 was found to be up-regulated by GnRH treatment. Ddx17 was 
previously found to act as a coactivator of β-catenin through forming a complex with β-
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catenin in the nucleus and subsequently promote the β-catenin target gene expression 
(Shin, Rossow et al. 2007). As Ddx17 was up-regulated by GnRH treatment, it may 
therefore stimulate β-catenin-dependent transcription in LβT2 cells. The enhanced 
stability of Ddx17 and Ddx5 have been hypothesized to be induced by their 
posttranslational modification (Shin, Rossow et al. 2007). As overexpression of Ddx5 
was found to occur simultaneously with the poly ubiquitination (Causevic, Hislop et al. 
2001) and phosphorylation of Ddx5 (Yang, Lin et al. 2005). Thus, GnRH may also 
regulate the modifications of Ddx17 and consequently induces the expression of Ddx17. 
Prkca was previously reported to function as a negative regulator of Wnt/ β-catenin 
signaling pathway (Gwak, Cho et al. 2006; Gwak, Jung et al. 2009). Depletion of Prkca 
inhibited GSK-3β-independent phosphorylation of β-catenin, and consequently stabilized 
the β-catenin. Prkca was found to be down-regulated by GnRH in our study; therefore the 
β-catenin may consequently be stabilized by GnRH in gonadotrope. It may also explain 
our finding that p-GSK-3β Ser 9 is not required for regulating β-catenin level in LβT2 
cells. Ppp2ca was down-regulated by GnRH treatment. Ppp2ca is the catalytic subunit of 
PP2A kinase (Janssens and Goris 2001), which was suggested to be essential for the 
degradation of β-catenin in Xenopus, and implicated to be the dominant inhibitor of Wnt 
signaling (Li, Yost et al. 2001). Later work done in a number of cell lines found that 
PP2A was required for the dephosphorylation of GSK-3β, which consequently enhanced 
the activity of GSK-3β and subsequently resulted in the degradation of β-catenin (Ivaska, 
Nissinen et al. 2002; Hildesheim, Belova et al. 2003; Lee, Seo et al. 2005). Furthermore 
Ser 9 of GSK-3β was suggested to be the target site by PP2A (Mitra, Menezes et al. 
2012). Based on the proposed actions of the identified proteins, we plotted a model of the 
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new interactive pathways (Figure 4.9). These findings advanced the current knowledge of 
GnRH signaling in gonadotrope cell line from regulating MAPK cascades to cross talk 
with Wnt signaling. However, further works will be needed to prove this proposed model.  
Last but not least, we have to acknowledge that this ICAT-based proteomic profiling, 
though provided useful information in signaling pathway, only recognize cysteine-
containing peptides, thus it inevitably missed out quite a number of non-cysteine 
contained proteins. Therefore a more comprehensive labeling method, such as iTRAQ is 
needed to complementary this study. Furthermore, translocation is often concurrent with 
the regulatory proteins, identification of the localization changes of proteins in the GnRH 
signaling may help to reveal crucial events involved in the regulation of gonadotropin 




Figure 4.9 Proposed model for cross talk between GnRH signaling and Wnt 
signaling. 
β-catenin, a crucial mediator of Wnt signaling, is perhaps stabilized by GnRH signaling 
through two mechanisms, which are shown as stabilization (a) and stabilization (b). 
Stabilization (a) is a β-catenin phosphorylation-dependent mechanism, where the 
phosphorylation of β-catenin, which results in the degradation, is modulated by either 
GSK-3β Ser 9 dependent-mechanism or GSK-3β Ser 9-independent mechanism. Prkca, 
which facilitates the phosphorylation and degradation of β-catenin was down-regulated 
by GnRH, therefore, possibly stabilizing β-catenin. Ppp2A, a phosphatase of GSK-3β Ser 
9, was down-regulated by GnRH, which may therefore stabilizing β-catenin through 
inactivating GSK-3β. Stabilization (b) is a β-catenin phosphorylation-independent 
mechanism, which is mediated by Cacybp-containing E3 ubiquitin complex. Cacybp is a 
negative regulator of β-catenin stabilization. The down-regulation of Cacybp by GnRH, 
possibly through Ca2+ signaling, may thus result in the stabilization of β-catenin. Besides 
the possibility of stabilizing β-catenin in gonadotrope, down-regulation of Cacybp may 
also enhance the activity of ERK 1/2 kinase, whereby facilitating the PKC pathway. 
Except for modulating β-catenin stability, GnRH may also modulate β-catenin 
transactivation activity through up-regulating Ddx 17, the co-activator of β-catenin.  
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Chapter 5. iTRAQ proteomic 
profiling of the cellular response 
induced by GnRH in gonadotrope 
cell line 
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5.1  Introduction 
GnRH serves as a key hormone to regulate reproduction of vertebrates. It is released from 
hypothalamus in a pulsatile manner and functions through GnRHR binding to induce the 
activation of multiple downstream signalling pathways, which eventually stimulate the 
synthesis and secretion of pituitary gonadotropins LH and FSH (Naor 2009). The 
variations in GnRH pulse frequency are associated with different physiological 
conditions as well as different developmental stages during the productive life. GnRH 
secretion is suppressed during the pre-pubertal period while an augmentation of GnRH 
pulse occurs at the onset of pubertal maturation. In adult males, the pulse of GnRH 
secretion is moderately consistent whereas in adult women it changes during the 
ovulatory menstrual cycle (Marshall, Dalkin et al. 1993). GnRH pulse frequency 
gradually increases during the follicular phase, which induces a surge in gonadotropin 
secretion and consequently causes ovulation (Ferris and Shupnik 2006).  The variation of 
GnRH pulses is also associated with pathologic conditions. Polycystic ovarian syndrome 
(PCOS) is the most common cause of infertility in women affecting 10% of the 
population (Ehrmann 2005; Azziz, Carmina et al. 2009). In patients with PCOS, 
reproductive cycle is disrupted by consistently elevated LH level and depressed FSH 
level, leading to an increase in androgen production by ovarian theca cells (Ehrmann 
2005). The synthesis and secretion of gonadotropins, essential for maintaining normal 
physiological conditions, are dependent on GnRH pulse frequency, perturbation of which 
induces infertility (Gharib, Wierman et al. 1990). In vivo studies have shown that the 
pulsatile stimulation by GnRH is more effective than sustained stimulation. The latter 
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causes chemical contraception and has been developed into the treatment of hormone-
dependent cancers (Conn and Crowley 1994). 
Variation in GnRH pulses leads to divergent LH and FSH secretion, rendering a 
mechanism by which a single hormone induction can cause differential changes in two 
distinct hormones released from the same gonadotrope cell. The alteration of GnRH 
pulsatility during the luteal and early follicular phases of the ovulatory cycle, favors the 
production of FSHβ, providing the increased pituitary FSH secretion essential for the 
recruitment and selection of the maturing ovum (REAME, SAUDER et al. 1984; 
Haisenleder, Dalkin et al. 1991; Kaiser, Jakubowiak et al. 1997; Burger, Haisenleder et 
al. 2004; Ferris and Shupnik 2006).  As noted above, GnRH pulsatility to the pituitary 
gonadotrope is crucial for the physiology and therapeutic manipulation of the 
reproductive system.  However, the underlying mechanism driving the differential 
regulation of gonadotropins, although likely rests on the ability of the gonadotrope to 
decipher different GnRH input patterns (Burger, Haisenleder et al. 2004; Ferris and 
Shupnik 2006; Ruf, Park et al. 2006), is still unclear.  
In last chapter, we utilized cICAT-based proteomics approach to compare differentially 
expressed proteins in whole cell lysate from mock-treated and GnRH-treated LβT2 cells. 
We identified a few proteins involved in PTMs and other signalling pathways other than 
MAPK cascades, which revealed the novel regulatory roles of GnRH and novel pathways 
GnRH may target. However, cICAT reagent can only label the proteins which carry 
cysteine-residue, thus it will inevitably miss out the non-cysteine containing proteins. 
Furthermore, cICAT-labeling only allows two-sample comparison, which limits the 
multiplex design of the experiments (Zieske 2006). These limitations may affect the 
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interpretation of GnRH signalling from a comprehensive perspective. To overcome these 
disadvantages, we used an alternative proteomic method - iTRAQ to perform 
comparative profiling of the nuclear proteomes of the mock-treated and GnRH-treated 
LβT2 cells. Rather than just a repetitive study, our iTRAQ study changed the GnRH 
treatment from continuous treatment to pulse treatment, which better represents the 
physiological condition (Lawson, Tsutsumi et al. 2007).  
Our study revealed that proteins involved in RNA processing, translation and 
chromosome organization were differentially regulated by GnRH pulse frequency. Our 
findings provide preliminary evidence showing the novel regulatory role of GnRH on 
gonadotropin. Furthermore, our findings suggest the involvement of Ca
2+
 signaling in 
decoding the GnRH pulse frequency. 
5.2 Results 
5.2.1 Analysis of the influence of differential GnRH frequency on nuclear 
proteome of the LβT2 cell line  
To better understand how GnRH signalling is decoded to differentially regulate LHβ and 
FSHβ gene expression, we carried out iTRAQ proteomics profiling of nuclear proteins 
alteration in GnRH-treated LβT2 cells. GnRH treatment was done for 30 min and 4 h, 
respectively. 30 min treatment represented the short frequency, whereas 4 h treatment 
mimicked the long frequency. After treatment, nuclear proteins were isolated from 
individual samples and subjected to 8-plex iTRAQ labeling. The details of the sample 
preparation were described in the chapter 3. The design of the iTRAQ labeling 
experiment is illustrated in Figure 5.1.  
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A strict cutoff threshold with unused protein score ≥ 1.3, corresponding to 95% C.I., was 
used as the protein identification criteria. Under this criteria, the 8-plex iTRAQ 
experiment identified 2733 proteins (Supplementary soft copy). Among these, 86 % 
proteins were identified with ≥ 2 - peptide (95% C.I.) matches, indicating high quality of 
the iTRAQ data. Next, the cutoff threshold of iTRAQ ratio was determined by a 
biological replicate method, which was proposed by (Gan, Chong et al. 2007). As shown 
in Figure 5.2, the final cut-off for both 30 min and 4 h GnRH-treatment were fixed at 1.5 






Figure 5.1 Schematic representation of the workflow of the iTRAQ–based 
proteomic profiling. 
8-plex iTRAQ labeling of the nuclear cell lysates from 30 min and 4 h mock-treated and 
GnRH-treated LβT2 cells was carried out in duplicates.  Duplicates from 30 min mock-
treated nuclear cell lysates were labeled with reagents113 and 115, and those from 30 
min GnRH-treated were labeled with reagents114 and 116. Similarly, duplicates from 4 h 
mock-treated nuclear cell lysates were labeled with reagents117 and 119, and those from 





Figure 5.2 Determination of the cut-off ratio for iTRAQ experiments.  
(a) 30 min GnRH-treatment (b) 4 h GnRH-treatment. The cut-off ratio were determined 
by calculating the percentage variation of  iTRAQ ratios of each protein from biological 
replicates; the resulting values were shown in horizontal axis. Next the numbers of the 
proteins whose iTRAQ ratio fell into the indicated percentage variation were counted; the 
numbers were shown in vertical axis. Then graphs were plotted and about 48% variation 




This cut-off threshold was applied to both replicates of 30 min GnRH-treatment as well 
as 4 h GnRH-treatment, and only the proteins met the criteria in both replicates were 
selected.  As a result, there were 108 proteins in 30 min GnRH-treatment, and 311 
proteins in 4 h GnRH-treatment, whose expression levels were considered to be 
significantly altered. The corresponding log10 ratios of these significantly altered 
proteins were plotted to demonstrate the correlation between the two replicates for each 
treatment. As shown in Figure 5.3, the correlation coefficients were 0.82 and 0.77 for 30 
min and 4 h treatments respectively, indicating acceptable variations in both datasets. 
Interestingly, among these significantly altered proteins, only 18 proteins were regulated 
by both 30 min and 4 h treatments with the same trend.  Furthermore, 5 proteins showed 
significantly opposite trends of alteration in the two different GnRH frequency treatments 
(Figure 5.4). These findings implicated that different GnRH frequency does possibly 




Figure 5.3 Correlation of iTRAQ ratios of the significantly altered proteins by 
GnRH-treatment between duplicates.  
The ratios used to plot the figures were the log10 ratios. (a) Correlation between 






Figure 5.4 Distribution of the significantly regulated proteins by 30 min GnRH-
treatment and 4 h GnRH-treatment. 
108 proteins in 30 min treatment and 311 proteins in 4 h treatment were identified as the 
significantly regulated proteins by GnRH. Among these, only 18 proteins were regulated 
by both 30 min and 4 h treatments with the same trend.  Furthermore, 5 proteins showed 
significantly opposite trends of alteration in the two different GnRH frequency treatments. 
 
5.2.2 Gene ontology study of the significantly altered proteins by GnRH induction 
5.2.2.1 Functional characterization of the overall proteins significantly regulated 
by GnRH induction 
To get a better insight into the functional relationship of the significantly altered proteins 
to the regulation of gonadotropins, we performed the gene ontology study. First, we 
applied IPA core analysis to all the significantly altered proteins. The top 3 molecular and 
cellular functions were RNA post-transcriptional modification, protein synthesis, and 
cellular assembly and organization (Figure 5.5). These findings were consistent with the 




Figure 5.5 Top ranked molecular and cellular functions of all the significantly 
altered proteins.  
Top ranked molecular and cellular functions of all the 396 proteins, which combined both 
of the 30 min- and 4 h-GnRH regulated proteins, were derived from the IPA core analysis. 
(Graph was redrawn based on the IPA output file) 
 
To investigate the mechanisms involved in the above molecular and cellular functions, 
we utilized STRING software to analyze the protein-protein interaction networks, which 
may help to discover the underlying mechanism. We entered the protein IDs of the 
significantly altered proteins into STRING open source software and looked for the top 
ranked biological processes. Among these, we selected three most relevant biological 
processes, which were mRNA processing, translation and chromosome organization, for 
further analysis. Next we inputted all the 2733 identified protein IDs to STRING, and 
only look for the proteins which were involved in the three most relevant biological 
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processes. After sorting these IDs, we analyzed the protein-protein interaction of the 
overall proteins involved in each of the three biological processes. These protein 






Figure 5.6 Analysis of interaction networks of (a) proteins involved in mRNA 
processing; (b) proteins involved in translation; (c) proteins involved in chromosome 
organization using STRING. 
The overall 2733 identified protein IDs were analyzed by STRING to screen for the 
interaction networks involved in (a) mRNA processing, (b) translation, and (c) 
chromosome organization. The analyses were carried out under the interactive network 
mode and the action view.  Densely connected networks were clustered and color coded.   
(red ↑ stands for up-regulation, green ↓ stands for down-regulation; dashed arrows refer 
to 30 min-GnRH treatment, solid arrows refer to 4 h-GnRH treatment) 
  
129 
Proteins involved in mRNA processing 
A recent paper reported that transcription and splicing are physically and functionally 
coupled (Montes, Becerra et al. 2012). Although GnRH-induced transcriptional 
regulation of gonadotropins has been studied extensively, little work has been done to 
investigate the role of GnRH in regulating splicing. In our study, we identified 19 
proteins which were known to participate in mRNA processing (Figure 5.6 (a)), were 
regulated by GnRH-treatment. Table 5.1 shows the list of these proteins, which were 
further grouped according to the sub-functions including serine –arginine proteins, RNA 
binding motif (Rbm) proteins, spliceosome component proteins and pre-mRNA 
processing proteins. Six out of the 19 proteins (31.6 %) were up-regulated by GnRH 
treatment, while the rest (68.4 %) were down-regulated. Among these proteins, only one 
protein, small nuclear ribonucleoprotein associated protein B (Snrpb), was down-
regulated by both 30 min and 4 h GnRH treatments.  
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Table 5.1 Proteins involved in mRNA processing. 














(4 h GnRH) 
Exp 
Pat. 
114:113 116:115 118:117 121:119 
Serine-arginine proteins 
2.34 49.1 IPI00830743.1 Srsf5 serine/arginine-rich 
splicing factor 5 
0.4786 0.6427 ↓↓ 1.0666 0.8017  
15.55 58.5 IPI00129323.1 Srsf3 Isoform Long of 
Serine/arginine-rich 
splicing factor 3 
2.355 2.5823 ↑↑ 2.8054 0.5808 
 
RNA binding motif (Rbm)proteins 
10 34.4 IPI00309195.2 Rbm14;Rbm4 Isoform 1 
of RNA-binding protein 4 
1.7865 1.0666  1.7378 1.5704 ↑↑ 
28.74 33.9 IPI00928541.1 Rbm25 Isoform 2 of 
RNA-binding protein 25 
0.6243 0.9039  0.4169 0.5916 ↓↓ 
6.97 21.9 IPI00798508.1 Rbm5 Isoform 2 of RNA-
binding protein 5 
1.0765 0.9727  0.7178 0.7516 ↓ 




0.4169 0.6792 ↓ 0.6252 1.7865  
spliceosome component proteins 
7.78 59.9 IPI00108143.1 Hnrnph2 Heterogeneous 
nuclear ribonucleoprotein 
H2 
2.3768 1.5136 ↑↑ 2.8054 0.4831  
26.99 48 IPI00480507.1 Prpf19 Isoform 1 of Pre-
mRNA-processing factor 
19 
0.5861 1.4454  0.4487 0.3733 ↓↓ 
8.67 42.4 IPI00114052.1 Snrpb Small nuclear 
ribonucleoprotein-
associated protein B 
0.4656 0.6546 ↓↓ 0.3281 0.4613 ↓↓ 
pre-mRNA processing proteins 
70.48 67.7 IPI00320016.7 Nono Isoform 1 of 
Non-POU domain-
containing octamer-
1.3062 2.1478 ↑ 2.3335 0.3373  
131 
binding protein 
7.94 24 IPI00263944.4 Mbnl3 Muscleblind-
like protein 3 
0.9727 0.9908  0.6918 0.6546 ↓ 
9.84 31.4 IPI00123333.5 Wbp11 WW domain-
binding protein 11 
0.5916 0.7178 ↓ 0.5546 0.8395  
2 41.8 IPI00121758.1 Tardbp TAR DNA-
binding protein 43 
0.7447 0.2938 ↓ 1.0375 0.5248  
10.14 26.2 IPI00170345.1 Cdc73 Parafibromin 0.5916 2.729  0.5152 0.4325 ↓↓ 
39.66 53.9 IPI00284444.5 Cdc5l Cell division 
cycle 5-related 
protein 
0.8318 1.2246  0.5702 0.7447 ↓ 
6 31.6 IPI00751759.1 Ptbp2 Isoform 1 of 
Polypyrimidine tract-
binding protein 2 
1.2706 0.9908  1.3428 1.3677 ↑ 





0.9376 0.7656  0.4656 0.7311 ↓ 
6 31.8 IPI00311968.1 Frg1 Protein FRG1 1.0471 0.7311  0.7447 0.7178 ↓ 




1.6749 1.4588 ↑ 0.9462 0.9727  
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Proteins involved in translation 
Except for transcriptional regulation of gonadotropins, GnRH was once reported to 
enhance the translation of LHβ gene (Nguyen, Santos et al. 2004). However, no other 
group published any findings about translational regulation of gonadotropins induced by 
GnRH. In this study, we found 28 proteins which were known to be involved in 
translation were regulated by GnRH (Figure 5.6 (b)). Table 5.2 shows the list of these 
proteins, which were further divided into sub-functional groups including eukaryotic 
translation initiation factors, aminoaceyl-tRNA synthetases, ribosomal proteins, and other 
proteins involved in translation. Eighteen out of 28 proteins (64.3 %) were down-
regulated by GnRH treatment, while the rest (35.7 %) were up-regulated. Among these 
proteins,  Eukaryotic translation initiation factor 5 (Eif5) and 39S ribosomal protein L43 
(Mrpl43) were down-regulated by both 30 min and 4 h GnRH-treatments. 
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Table 5.2 Proteins involved in translation. 












(30 min GnRH) Exp 
Pat. 
iTRAQ ratio 
(4 h GnRH) Exp 
Pat. 
114:113 116:115 118:117 
121:11
9 
eukaryotic translation initiation factors 
6.46 27.7 IPI00187443.1 Eif5;LOC100047658 
Eukaryotic translation 
initiation factor 5 
0.4169 0.52 ↓↓ 0.3373 0.6252 ↓↓ 
10.5
4 
38.9 IPI00119806.6 Eif2a Isoform 1 of 
Eukaryotic translation 
initiation factor 2A 
0.2559 0.7516 ↓ 0.6546 0.8551  
5.6 15.3 IPI00463573.3 Eif3l Eukaryotic 
translation initiation 
factor 3 subunit L 
0.5248 0.492 ↓↓ 1.2359 2.2491 
 35.5
7 
70.7 IPI00116302.3 Eif2s2 Eukaryotic 
translation initiation 
factor 2 subunit 2 
0.9817 1.0666  0.3597 0.4571 ↓↓ 
9.35 26.2 IPI00116761.1 Eif2b1 Translation 
initiation factor eIF-
2B subunit alpha 
0.9727 1.6596  0.5754 0.5598 ↓↓ 
3.01 33.6 IPI00119057.1 Eif4e Eukaryotic 
translation initiation 
factor 4E 
1.1482 0.7798  2.7542 1.5136 ↑↑ 
aminoacyl-tRNA synthetases 




0.3467 0.5012 ↓↓ 1.2589 0.7447 
 4 16.3 IPI00112555.3 Gars Glycyl-tRNA 
synthetase 
0.4406 0.5445 ↓↓ 1.3183 0.2148 
 12.1
5 
24.4 IPI00273767.3 Dars2 Aspartyl-tRNA 
synthetase, 
mitochondrial 
1.4997 2.8054 ↑ 1.0093 1.1912  
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0.7244 0.7244 ↓ 1.0093 1.1912  
2 14 IPI00459324.1 Cars2 Putative 
uncharacterized 
protein 
0.787 1.0471  0.5445 0.6855 ↓ 
6.66 23.2 IPI00469317.4 Sars Seryl-tRNA 
synthetase, 
cytoplasmic 
0.5012 1.3932  1.9055 1.4723 ↑ 
4.01 15.3 IPI00396833.1 Yars2 Tyrosyl-tRNA 
synthetase, 
mitochondrial 
1.2706 1.0186  1.7378 2.0324 ↑↑ 
9.59 28.5 IPI00321308.4 Aars Alanyl-tRNA 
synthetase, 
cytoplasmic 
0.879 0.929  2.2284 5.6494 ↑↑ 
7.94 33 IPI00223415.4 Nars Asparaginyl-
tRNA synthetase, 
cytoplasmic 




58 IPI00323819.3 Rps20 40S 
ribosomal protein 
S20 
0.5808 3.0479  2.5119 1.6444 ↑↑ 
2 41.4 IPI00331121.4 Rpl38 60S ribosomal 
protein L38 
0.7447 1.3062  0.4406 0.6368 ↓↓ 
37.5
7 
55.6 IPI00111412.3 Rpl4 60S ribosomal 
protein L4 
0.3767 1.3677  0.5495 0.6252 ↓↓ 
2 9.6 IPI00131988.1 Mrpl49 39S 
ribosomal protein 
L49, mitochondrial 
0.6982 0.7516 ↓ 0.3945 1.0375  
4.3 17.9 IPI00133778.1 Mrpl14 39S 
ribosomal protein 
L14, mitochondrial 
1.3428 1.4723 ↑ 1.2823 0.6486 
 4.92 32 IPI00225318.3 Mrpl22 39S 
ribosomal protein 
L22, mitochondrial 
1.6596 1.3428 ↑ 0.9908 1.0186  
4.03 35.4 IPI00121359.4 Mrpl4 39S 
ribosomal protein 
L4, mitochondrial 




5.61 42.1 IPI00761722.2 Mrpl43 39S 
ribosomal protein 
L43, mitochondrial 
0.5754 0.5105 ↓↓ 0.5916 0.5346 ↓↓ 
5.77 48.9 IPI00378520.4 Mrpl41 39S 
ribosomal protein 
L41, mitochondrial 
0.863 0.3133  0.6486 0.6486 ↓↓ 




1.1912 1.1066  0.4742 0.7379 ↓ 
other proteins involved in translation 
10.0
3 
35.1 IPI00109501.1 Mrrf Ribosome-
recycling factor, 
mitochondrial 
0.9817 1.0765  0.5346 0.6368 ↓↓ 
9.76 23.1 IPI00312468.5 Etf1 Eukaryotic 
peptide chain release 
factor subunit 1 
0.5012 0.6486 ↓↓ 0.8318 1.0471  
19.9
5 
31.3 IPI00230283.5 Gfm1 Elongation 
factor G, 
mitochondrial 
1.3804 1.5276 ↑ 1.1482 0.6194  
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Proteins involved in chromosome organization 
A total number of 40 GnRH-regulated proteins were involved in chromosome 
organization (Figure 5.6 (c)). 35 proteins (87.5 %) were regulated by 4 h GnRH-treatment 
while only 8 proteins (20 %) were regulated by 30 min GnRH-treatment. Msh2 and 
Dnajc2 Uncharacterized proteins were found up-regulated by both 30 min and 4 h GnRH-
treatments. However, Hmgn1 was found up-regulated by 30 min while down-regulated 
by 4 h GnRH-treatment. They were sub-divided to those involved in PTMs of N-terminal 
tails, those having structural roles in chromatin, those involved in DNA binding, and 
those involved in other functions (Table 5.3). Interestingly, over 50 % of the proteins 
which were involved in the chromosome organization were related to PTMs of the N-
terminal tails, and the majority of these proteins were regulated by 4 h GnRH-treatment. 
PTMs of the N-terminal tail of each core histone, which include acetylation, methylation, 
phosphorylation, ubiquitylation and sumoylation, have been found to play crucial roles in 
the regulation of cellular processes through modulating the chromatin structures 
(Kooistra and Helin 2012). Among all the modifications, histone deacetylation has been 
recently studied in the gonadotrope cells (Lim, Luo et al. 2007; Melamed 2008). It was 
found that the repression of FSHβ gene expression caused by HDACs can be overcomed 
by GnRH. Besides histone deacetylation, acetylation has also been implicated to be 
involved in the regulation of gonadotropins (Melamed, Kadir et al. 2006), which has been 
discussed in Chapter 4. 
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Table 5.3 Proteins involved in chromosome organization. 













(4 h GnRH) 
Exp 
Pat. 
114:113 116:115 118:117 121:119 
proteins involved in PTMs of N-terminal tails 
5.04 15.1 IPI00831095.1 Ezh2 
Uncharacterized 
protein 
2.4889 2.0137 ↑↑ 1.3932 0.912  





1.0864 0.8954  0.5495 0.3311 ↓↓ 




1.1169 0.8551  0.6546 0.5598 ↓↓ 




1.556 3.02 ↑↑ 0.0871 0.2228 ↓↓ 





1.2823 0.9817  0.631 0.413 ↓↓ 
69.27 36.8 IPI00857777.1 Chd4 
Uncharacterized 
protein 
1.2359 1.3305  0.1941 0.2512 ↓↓ 
20.31 32.4 IPI00652110.1 Brd4 
Uncharacterized 
protein 
1.1482 0.9817  0.7447 0.6668 ↓ 
14.3 44.4 IPI00830720.1 Morf4l2 
Uncharacterized 
protein 
0.7047 1.3062  0.5445 0.6668 ↓ 
12 24.3 IPI00278600.1 Morf4l1 Isoform 1 
of Mortality factor 
4-like protein 1 
1.1169 1.1695  0.52 0.6026 ↓↓ 
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4 18.6 IPI00720110.2 1600027N09Rik 
Uncharacterized 
protein 
0.6982 0.5445 ↓ 0.492 0.7943  
13.95 22.7 IPI00274795.4 Ncor1 
Uncharacterized 
protein 
1.2823 0.8166  0.4742 0.4786 ↓↓ 




0.929 0.7178  0.2655 0.597 ↑↑ 
10.39 35.8 IPI00122698.1 Rbbp7 Histone-
binding protein 
RBBP7 
1.2589 0.7244  0.7244 0.7447 ↓ 
27.54 33.4 IPI00857769.1 Pbrm1 
Uncharacterized 
protein 
0.9376 0.9817  0.2965 0.3837 ↓↓ 
16.44 28.1 IPI00404707.1 Rbm14 Isoform 1 
of RNA-binding 
protein 14 
1.0471 1.0471  0.5598 0.4613 ↓↓ 
24.43 54.8 IPI00127415.1 Npm1 
Nucleophosmin 
0.631 1.1912  0.2333 0.3467 ↓↓ 
10 28.7 IPI00396676.1 Suz12 Polycomb 
protein Suz12 
0.9204 0.6138  0.2858 0.2704 ↓↓ 
28.9 30.9 IPI00133839.1 Chaf1a Chromatin 
assembly factor 1 
subunit A 
2.466 0.863  0.6486 0.6138 ↓↓ 
18.77 43.9 IPI00133985.1 Ruvbl1 RuvB-like 
1 
0.7943 0.912  0.2535 0.6026 ↓↓ 
12.02 19 IPI00229432.8 Bptf 
Uncharacterized 
protein 
0.9727 1.0765  0.5916 0.6607 ↓↓ 
5.31 24.5 IPI00923656.1 Baz1b Isoform 1 of 
Tyrosine-protein 
kinase BAZ1B 
0.896 0.6458  0.7516 0.3631 ↓ 



















Beta-I of Protein 


























1.4454 0.9817  0.5702 0.6427 ↓↓ 
proteins have structure roles in chromatin 
26.06 23.5 IPI00357096.3 Nipbl Isoform 2 of 
Nipped-B-like 
protein 
2.0324 0.6138  0.1127 0.2582 ↓↓ 
8.12 11.1 IPI00459898.3 Espl1 Separin 1.4322 1.1066  1.4588 1.7061 ↑ 
18.33 29.6 IPI00135443.2 Top2b DNA 
topoisomerase 2-
beta 
0.302 0.7727  0.2312 0.52 ↓↓ 
85.84 39.3 IPI00122223.1 Top2a DNA 
topoisomerase 2-
alpha 
0.3981 1.0093  0.0394 0.2355 ↓↓ 
proteins involved in DNA replication 
5.62 11.5 IPI00125142.2 Msh3 DNA 
mismatch repair 
protein Msh3 
1.3932 1.028  1.6749 1.556 ↑↑ 
36.02 36.6 IPI00118158.1 Msh2 DNA 
mismatch repair 
protein Msh2 
0.4169 0.4831 ↓↓ 0.5058 0.3499 ↓↓ 




1.977 0.3837  0.3698 0.1047 ↓↓ 
22.79 53.5 IPI00648350.2 Trp53 cellular 
tumor antigen p53 
isoform b 
0.9908 0.9908  1.7378 1.3677 ↑ 
proteins involved in DNA binding 
16.15 45.8 IPI00227720.3 Dek Protein DEK 0.5649 0.879  0.4018 0.1259 ↓↓ 
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1.2134 1.1169  0.7656 0.7516 ↓ 
11.76 30.2 IPI00856664.1 Dnajc2 
Uncharacterized 
protein 
0.3192 0.6427 ↓↓ 0.1837 0.4786 ↓↓ 
8 17 IPI00225459.1 Lrwd1 Leucine-
rich repeat and WD 
repeat-containing 
protein 1 
1.3677 1.6904 ↑ 0.2188 0.9727  
21.77 33 IPI00118853.1 Mre11a Isoform 1 
of Double-strand 
break repair protein 
MRE11A 
0.8395 0.8395  0.6252 0.6081 ↓↓ 




0.7727 1.028  1.4454 1.4454 ↑ 
proteins involved in other functions 
4 17.9 IPI00321739.1 Akap8 A-kinase 
anchor protein 8 
0.929 1.0666  1.556 1.4454 ↑ 




isoform 1 precursor 
0.871 0.7112  0.6546 0.4875 ↓↓ 
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5.2.2.2 Functional characterization of the proteins only regulated by 30 min or 4 h 
GnRH-induction 
To further investigate the mechanisms which cause the LHβ and FSHβ to be 
differentially regulated by different GnRH pulses, we then analyzed the molecular 
functions of the proteins which were only regulated by 30 min or 4 h GnRH-treatment. 
Surprisingly, we found a few functions differentially presented among all the top-12 
ranked molecular functions of each treatment. As shown in Figure 5.7, the function of 
calmodulin-binding was only found in 30 min GnRH-regulated proteins; in addition all 
the proteins identified with this function were up-regulated by 30 min GnRH-induction. 
While, the function of chromatin regulator was only found in 4 h GnRH-regulated 
proteins; and all the identified proteins involved in this function were down-regulated by 
4 h GnRH-treatment. The differentially regulated proteins involve in these functions were 





Figure 5.7 GO analysis of differentially regulated proteins by different GnRH 
frequency induction. 
GO analysis was done using DAVID software. The percentiles of genes involved in each 
molecular function were plotted against the corresponding molecular function (bar). The 
Log10 P-value of each molecular function was also indicated in the graph (line). Only the 
molecular function with P <0.05 were shown in this graph. (a) The significantly altered 
proteins only regulated by 30 min GnRH-treatment (b) The significantly altered proteins 
only regulated by 4 h GnRH-treatment.  
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Table 5.4 Proteins involved in CaM-binding. 
 
Table 5.5 Proteins involved in chromatin regulation. 





Accession # Name 
iTRAQ ratio 
(4 h GnRH) 
Exp 
Pattern 
 118:117 121:119 
10.08 29.5 IPI00317722.3 Dmap1 Isoform 1 of DNA methyltransferase 
1-associated protein 1 
0.631 0.413 ↓ 
10 28.7 IPI00396676.1 Suz12 Polycomb protein Suz12 0.2858 0.2704 ↓ 
69.27 36.8 IPI00857777.1 Chd4 Uncharacterized protein 0.1941 0.2512 ↓ 
18.77 43.9 IPI00133985.1 Ruvbl1 RuvB-like 1 0.2535 0.6026 ↓ 
12 24.3 IPI00278600.1 Morf4l1 Isoform 1 of Mortality factor 4-like 
protein 1 
0.52 0.6026 ↓ 
8.02 17.9 IPI00762411.2 Whsc1 Isoform 1 of Probable histone-lysine 
N-methyltransferase NSD2 
0.5495 0.3311 ↓ 
15.64 25.5 IPI00875892.1 Kdm2a Uncharacterized protein (Fragment) 0.5105 0.3467 ↓ 
13.95 22.7 IPI00274795.4 Ncor1 Uncharacterized protein 0.4742 0.4786 ↓ 
16.65 37.5 IPI00649685.3 Smarcd2 Isoform 1 of SWI/SNF-related 
matrix-associated actin-dependent regulator 
of chromatin subfamily D member 2 
0.6252 0.6138 ↓ 
31.65 43 IPI00122696.6 Rbbp4 Uncharacterized protein 0.3908 0.5105 ↓ 
2.03 16.9 IPI00660988.3 Mll5 Isoform 1 of Histone-lysine N-
methyltransferase MLL5 
0.6546 0.5598 ↓ 
100.52 52 IPI00469323.3 Dnmt1 DNA (cytosine-5)-methyltransferase 
1 isoform 2 





Accession # Name 
iTRAQ ratio  




21.39 38 IPI00387580.2 Add3 Isoform 1 of Gamma-adducin 4.1305 2.5823 ↑ 




2.21 27.9 IPI00119111.2 Cnn3 Calponin-3 1.5276 1.6444 ↑ 
15.22 31.5 IPI00742310.5 Ewsr1 RNA-binding protein EWS 1.556 2.0137 ↑ 
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27.54 33.4 IPI00857769.1 Pbrm1 Uncharacterized protein 0.2965 0.3837 ↓ 
4.72 67.7 IPI00338745.4 LOC100044391;Hmgn1 Non-histone 
chromosomal protein HMG-14 
0.0871 0.2228 ↓ 
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Calmodulin (CaM) is a notable effector mediating GnRH-induced Ca
2+
 signaling 
downstream pathways through MAPK-independent manner (Melamed, Savulescu et al. 
2012).  Diverse studies have indicated the involvement of Ca
2+ 
in the expression of 
gonadotropins (Naor 2009), and also suggested that Ca
2+ 
sensing is a potential factor to 
decode GnRH pulse frequency (Haisenleder, Yasin et al. 1997). Therefore, our findings 
that the function of CaM binding is only presented in the proteins which were 
significantly regulated by 30 min supported the previous hypothesis. As the involvement 
of Ca
2+ 
signaling in decoding the GnRH pulse frequency has been further suggested, we 
therefore used STRING to identify the significantly regulated proteins which were 
involved in Ca
2+ 
signaling. These proteins were shown in Table 5.6. 
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Accession # Name 
     iTRAQ ratio 
(30 min treatment) 
  iTRAQ ratio 
(4 h treatment) 
114:113 116:115 
Exp 
Pat. 118:117 121:119 
Exp  
Pat. 
2.08 18.3 IPI00130419.1 Prkce Protein kinase C 
epsilon type 
1.6444 1.5996 ↑ 1.1066 2.729  
4.23 13.7 IPI00757755.1 Prkcb Isoform Beta-I of 
Protein kinase C beta type 
4.3251 1.3305 ↑ 0.2466 1.4322  
8.09 18.9 IPI00338964.3 Atp2a2 Isoform 
SERCA2B of 
Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 
2 
0.7586 0.4656 ↓ 0.5152 0.6026 ↓ 
17.1 49.8 IPI00911151.1 Nucb2 nucleobindin-2 
isoform 2 
0.4487 0.6607 ↓ 1.3183 1.4191 ↑ 
62.75 54.9 IPI00876528.1 Gtf2i Isoform 5 of 
General transcription 
factor II-I 
0.9204 0.9204  0.6138 0.3908 ↓ 





5.3.1 Proteins involved in RNA processing 
Alternative splicing (AS) is a unique process in higher eukaryote, which is driven by the 
spliceosome, a large ribonucleoprotein complex composed of small nuclear RNAs 
(snRNAs) and proteins (Fox-Walsh, Dou et al. 2005; Görnemann, Kotovic et al. 2005). It 
is regulated by positive and negative cis-elements such as exonic and intronic splicing 
silencers and enhancers (ESS, ISS, ESE, and ISE) as well as trans-acting factors such as 
heterogeneous nuclear ribonucleoproteins (hnRNPs) and serine/arginine-rich (SR) 
proteins through a combinatorial interaction (Wu and Maniatis 1993). Besides, AS was 
also known to be regulated in a cell type- or developmental stage-specific manner, which 
were orchestrated by the amounts and activities of cellular splicing factors, such as RNA-
binding motif (Rbm) proteins (Matlin, Clark et al. 2005). These proteins exert their 
functions through interacting with hnRNPs or SR proteins (Glisovic, Bachorik et al. 
2008). 
In our study, we found the spliceosome component proteins hnRNP h2 and Prpf 19 were 
differentially regulated by 30 min and 4 h GnRH, indicating different spliceosomes may 
be formed under different GnRH frequencies and therefore facilitating the AS of different 
gonadotropins. We also identified a number of Rbm proteins and most of them were 
regulated by 4 h GnRH-treatment. These proteins have been implicated in other context 
to modulate the pre-mRNA processing through their functional motifs (Zhou, Ou et al. 
2008; Lin and Tarn 2011; Niu, Jin et al. 2012). So identification of the interacting 
partners of these Rbms will be needed to elucidate how they regulate pre-mRNA 
processing in the events of gonadotropin regulation. We also found a number of SR 
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proteins were regulated by 30 min GnRH-treatment. SR proteins are essential factors 
participating in the maturation of the spliceosome. These proteins have a C-terminal 
domain rich in Arg-Ser repeats (RS domain) and one or two N-terminal RNA recognition 
motifs (RRMs). RRMs modulate SR protein interactions in the spliceosome by binding 
short mRNA sequences, and the phosphorylation of RS domain is required for 
translocation of SR proteins into the nucleus, and the translocation was suggested to be 
crucial for alternative splicing, mRNA export, and other RNA  processing events (Ghosh 
and Adams 2011). We found that the SR proteins Sfrs3 was up-regulated and Sfrs5 was 
down-regulated by 30 min GnRH-treatment in LβT2 nuclear fraction, indicating 
translocation may happen, and most likely be triggered by GnRH-induced 
phosphorylation. SR protein can be phosphorylated by two protein kinase families, one of 
which is the family of SRPKs. These kinases directly affect nuclear import of SR proteins 
(Gui, Lane et al. 1994). Furthermore, phosphorylation induced by GnRH were mainly 
through MAPK pathways, and a previous study identified a small insert, called MAPK 
insert, located in SPPK1 kinase domain (Zhou, Qiu et al. 2012). So we proposed that 
GnRH might cause phosphorylation and subsequent translocation of SR proteins through 
MAPK pathways, and result in the regulation of gonadotropin mRNA splicing and 
maturation. The involvement of GnRH-regulated proteins in RNA processing was 
summarized in Figure 5.8. Further works are needed to prove this hypothesis. 
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Figure 5.8 The involvement of GnRH-regulated proteins in RNA processing. 
GnRH pulse differentially regulates the trans-acting factors of AS process, including 
hnRNP h2, Prpf19, and SR proteins. These factors may consequently mediate the GnRH 
signals to regulate the pre-mRNA splicing of gonadotropins. Beside, GnRH also 
regulates a number of Rbms. These Rbms may interact with hnRNP h2, or Prpf19, or SR 
proteins, or with other splicing factors and eventually acts on the AS process. (solid 
arrows indicate the results derived from literature, and dashed arrows indicate the 




5.3.2 Proteins involved in translation 
Eukaryotic cap-dependent translation initiation involves a process to form an elongation-
competent 80S ribosome. This process requires the cooperation of at least nine eukaryotic 
initiation factors (eIFs) and comprises two steps: the formation of 48S initiation 
complexes and the joining of 48S complexes with 60S subunits (Jackson, Hellen et al. 
2010). In our study, we identified several eukaryotic translation initiators, whose 
expression levels were altered by GnRH, indicating the impact of GnRH on the process 
of translation initiation. Our study found that Eif5 was down-regulated by both 30 min 
and 4 h GnRH-treatments. The function of eIF5 was implicated in the final step of AUG 
selection- release of Met-tRNAi from eIF2-GDP (Sokabe, Fraser et al. 2012). Moreover, 
eIF5 was a critical component of eIF2(αP) regulatory complex, which modulated 
phosphorylation of eIF2,  restricting recycling of eIF2 in the process of translation 
initiation (Jennings and Pavitt 2010). Therefore, our finding is consistent with the 
expectation that reduced amount of Eif5 will contribute to less inhibitory effect on eIF2 
circulation, thus facilitating the process of translation initiation. 
Besides, eIF4E was up-regulated by 4 h GnRH-treatment while without any significant 
changes by 30 min GnRH-treatment. The phosphorylation of eIF4E has been implicated 
to be sensitive to GnRH treatment in LβT2 cells, and was found through ERK activation 
(Nguyen, Santos et al. 2004). So how the phosphorylation status affect the association 
between eIF4E and different translation initiation complexes would be an interesting 
subject to explore. eIF3 is a large complex composed of 13 subunits (a-m) in mammals, 
playing a crucial role in recruiting mRNA to 43S ribosome (Jackson, Hellen et al. 2010). 
We found Eif3l was down-regulated upon 30 min GnRH-treatment, while slightly up-
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regulated (not significant for both replicates) by 4 h GnRH treatment, implicated that the 
translation initiation factors may differentially act on the translation machinery driven by 
GnRH pulse variance. 
We also identified a number of aminoacyl-tRNA synthetases (aa-RSs), which are 
regulated by GnRH treatment. aa-RSs are crucial regulators for faithful translation from 
mRNA to protein, a process involving two steps: forming the aminoacyl-tRNAs (aa-
tRNAs) by aa-RSs and delivering them to the ribosome by elongation factors (Ogle and 
Ramakrishnan 2005). The specificity of the amino acid substrates is achieved by means 
of preferential binding of the cognate amino acids and selective editing of near-cognate 
amino acids. So far there are two types of intrinsic proofreading activities, either before 
(pre-transfer editing) or after (post-transfer editing) the mis-activated amino acid is 
attached to tRNA, have been reported to be carried out by aa-RSs (Ling, Reynolds et al. 
2009). In this study, we found GnRH treatment caused the differential regulation of aa-
RSs, which have never been reported by other groups before. Further validation will be 
needed to identify the specific targets of the aa-RSs. The involvement of GnRH-regulated 





Figure 5.9 The involvement of GnRH-regulated proteins in translation. 
GnRH regulates several translational initiation factors, which may consequently affect 
the assembling of translation initiation machinery from corresponding steps. GnRH also 
regulates the aaRSs, which may subsequently affect the process of aa-tRNA generation. 
The effect on translational initiation factors and aaRSs, will function together on the 
regulation of gonadotropin translation. 
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5.3.3 Proteins involved in chromosome organization 
In eukaryotic cells, DNA is packed in the nucleus to form a highly organized form of 
chromosome. Nucleosome is the basic unit of chromatin. It is made of 145-147 bps of 
DNA which is wrapped around an octamer consisting of two of each of the histones H2A, 
H2B, H3 and H4.  Nucleosome is repeated and chromatin is further condensed 
throughout the genome. It has been suggested that the specific composition of chromatin 
is an important determinant of the cellular function (Kouzarides 2007). PTMs of the N-
terminal tails of each core histone, which modulate the chromatin structure, play crucial 
roles in the regulation of cellular processes. Such PTMs include acetylation, methylation, 
phosphorylation, ubiquitylation and SUMOylation (Kooistra and Helin 2012). Among all 
the PTMs, histone deacetylation has been recently studied in the gonadotrope cells (Lim, 
Luo et al. 2007; Melamed 2008). It was found that the HDACs caused repression of 
gonadotropin gene expression can be overcomed by GnRH signaling. In our study, we 
found a number of proteins which were predicted to interact with HDACs. NcoR1 
uncharacterized protein was down-regulated by GnRH-treatment. NcoR is one of the 
well-known corepressors that lack enzymatic activity but can recruit HDACs to the 
specific gene loci or to stabilize the HDAC complex (Glass and Rosenfeld 2000; Jepsen 
and Rosenfeld 2002). The N-terminus of NcoR is composed of three repression domains, 
which allow interaction with several HDACs and also with mSin3A, another common 
corepressor. Sin3 can directly interact with HDACs and DNA-bound factors through its 
multi-domain to form a scaffold protein (Glass and Rosenfeld 2000; Grozinger and 
Schreiber 2002). So it is possible that decreased amount of NCoR1 by GnRH in nucleus 
will result in less HDACs recruited to the gonadotropin promoters. Further work will be 
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done to find the specific HDACs associated with NcoR1 and also the specific promoter 
targeted by the HDAC repressor complex.  
Chd4 uncharacterized protein was also down-regulated by GnRH-treatment. Chd4 is the 
core subunit of a chromatin remodeling complex, the Nucleosome Remodeling and 
Deacetylase (NuRD) complex, which plays important roles in repressing transcription in 
many context of biological processes (Xue, Wong et al. 1998; Pegoraro, Kubben et al. 
2009). Chd4 is composed of three crucial functional domains, a SNF2-type ATPase 
domain, a tandem plant homeodomain (tPHD), and a tandem chromodomain (tCHD). 
tPHD domain is found in many chromatin remodeling factors and has been suggested to 
be involved in nucleosome/histone binding (Bienz 2006; Peña, Davrazou et al. 2006; Shi, 
Kachirskaia et al. 2007). tCHD domain was shown to mediate chromatin interaction by 
directly binding with DNA, RNA or methylated histone H3 (Akhtar, Zink et al. 2000; 
Bouazoune, Mitterweger et al. 2002; Flanagan, Mi et al. 2005; Flanagan, Blus et al. 2007). 
NuRD is a transcription repressor. it has been reported to regulate a diversity of 
biological processes through forming multicomplex with Chd4 and Chd4-associated 
subunits, such as with HDAC1 and HDAC2 (Bowen, Fujita et al. 2004). Therefore, Chd4 
has a great potential to regulate the transcription of gonadotropins through mediating the 
formation of repressor complex with regulatory proteins or HDACs. Future work will be 
carried out to identify these Chd4-associated factors.  
Hmgn1 was found to be differentially regulated by 30 min and 4 h GnRH-treatment. This 
protein is able to bind specifically to nucleosomes (Bustin and Reeves 1996), especially 
on the regulatory region (Cuddapah, Schones et al. 2011).  The presence of this protein 
on the chromatin and nucleosomes thereby facilitates the accessibility of other regulatory 
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factors to their targets. The accessibility of a molecule to the chromatin is quite 
dependent on its cellular localization. The nuclear Hmgn1 level is higher upon 30 min 
than 4 h GnRH-treatment thus indicating different GnRH pulse frequency may affect the 
nucleus translocation of Hmgn1, and Hmgn1 may have more chance to associate with 
nucleosome under 30 min treatment. Except for the cellular localization, the PTMs of 
Hmgn1, mainly through acetylation and phosphorylation, were also suggested to be 
crucial for modulating the activity of Hmgn1 (Pogna, Clayton et al. 2010).  So whether 
different GnRH pulses also regulate the modification of Hmgn1is also worth to be 
investigated. We believe the correlation between the GnRH pulse and the cellular 
localization as well as modification of Hmgn1 may help us to understand the mechanism 
of GnRH pulse frequency decoding in terms of chromatin remodeling. The involvement 





Figure 5.10 The involvement of GnRH-regulated proteins in chromosome 
organization. 
GnRH down-regulates NcoR and Chd4. NcoR is a chromosome co-repressor, which 
works together with Sin3A to recruit HDACs to the chromosome and inhibit the 
transcription of the target chromosome. Chd4 is the subunit of NuRD complex, which 
also recruits HDACs to the chromosome and inhibits the transcription of the target 
chromosome. So down-regulation of NcoR and Chd4 by GnRH may inhibit the 
repression on the gonadotropin genes. Hmgn1 is differentially regulated by 30 min and 4 
h GnRH-treatment. The nucleus translocation and modification of Hmgn1 were possibly 
affected. So far all the known factors involved in chromosome remodeling targeted FSHβ 
gene transcription. (solid arrows indicate the results derived from literature, and dashed 




5.3.4  Ca2+ signaling involved in decoding the GnRH pulse frequency 
In this study we identified a number of proteins involved in regulating Ca
2+ 
signaling are 
differentially regulated by GnRH pulse frequency. Ca
2+ 
signaling has been suggested to 
be involved in decoding the GnRH frequency driven by the intermittent changes in Ca
2+
 
concentration (Haisenleder, Yasin et al. 1997). Although external calcium influx and 
calcium mobilization from internal IP3-sensitive stores (Naor, Capponi et al. 1988; 
Stojilković, Iida et al. 1991; STOJILKOVIC, REINHART et al. 1994) have been 
suggested to be the causes of intermittent changes in Ca
2+
 concentration, regulators of G-
protein signaling (RGS) proteins, which serve as GTPase-activating proteins for Gαi, 
Gαq, and Gα12 subunits (Ross and Wilkie 2000), have been implicated in mediating 
GnRH-induced Ca
2+ 
signaling (Naor, Capponi et al. 1988).  However, it is not yet clear 
how GnRH regulates these processes.  
In our study, Gtf2i was found to be down-regulated by 4 h GnRH-treatment, but not by 
30 min GnRH-treatment. Gtf2i was reported to negatively regulate the transient receptor 
potential channel 3 (TRPC3), a Ca
2+
 channel, through binding with phospholipase C 
(PLC) and inhibit the entry of Ca
2+ 
 (Park and Dolmetsch 2006). So it is possible that 4 h 
GnRH-treatment decreases the level of Gtf2i, and consequently allows the PLC binding 
with TRPC3 instead of Gtf2i, therefore facilitating the activation of TRPC3 calcium 
channel, and results in increased Ca
2+ 
influx. On the contrary, 30 min GnRH-treatment 
does not affect the level of Gtf2i therefore won’t affect the binding of TRPC3 with PLC 
and the consequent effects. Nucb2 was another potential Ca
2+ 
signaling regulator. Nucb2 
was down-regulated by 30 min GnRH-treatment while up-regulated by 4 h GnRH-
treatment. Nucb2 was found to have a common motif with Gα-interacting vesicles-
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associated protein (GIV), which is the first non-receptor guanine nucleotide exchange 
factor (GEF) that activates Gαi (Garcia-Marcos, Kietrsunthorn et al. 2011). Increased 
level of Nucb2, which was induced by 4 h GnRH-treatment, may activate Gαi and 
downstream PLCβ, which may lead to the increasing of Ca2+ concentration. On the 
contrary, decreasing Nucb2 by 30 min GnRH-treatment may conversely regulate Ca
2+ 
concentration. Except for regulating Ca
2+
 concentration, we also identified the proteins 
which may play roles in mediating Ca
2+ 
signaling to gonadotropin genes. We identified a 
group of CaM-binding proteins which were only regulated by 30 min treatment. As CaM 
is a downstream effector of GnRH-induced Ca
2+ 
signaling, these CaM-binding proteins 
may function as CaM-downstream effectors to gonadotropins through CaMKs pathway 
or calcineurin pathway (Melamed, Savulescu et al. 2012), or other novel pathways. We 
also identified a protein, ACTN4, which was differentially regulated by different GnRH 
pulse frequency. ACTN4 has a CaM-like domain, so it might mimic the function of CaM 
and regulate the gonadotropins. Hence future work will be done to validate the functions 
of these proteins. The involvement of the proteins in Ca
2+ 





Figure 5.11 The involvement of GnRH-regulated proteins in Ca
2+ 
signaling. 
Gtf2i was differentially regulated by GnRH pulse frequency and consequently affect the 
binding of PLC and TRPC3, which eventually results in varied Ca
2+ 
influx. Nucb2 was 
differentially regulated by GnRH pulse frequency, and differentially acts on Gαi and 
downstream PLCβ, which may lead to the varied Ca2+ concentration. A group of CaM-
binding proteins were only regulated by 30 min GnRH treatment. They may act on the 
gonadotropins through CaMKs pathway or calcineurin pathway or other novel pathways. 
ACTN4 was differentially regulated by different GnRH pulse frequencies. Its CaM-like 
domain may function similar as CaM, which affects CaMKs pathway or calcineurin 
pathway or other novel pathways, results in the regulation of gonadotropins. (solid arrows 
indicate the results derived from the literature, and dashed arrows indicate the speculated 
results; ↑ stands for up-regulation, ↓ stands for down-regulation.) 
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In conclusion, our study provides preliminary evidence showing the novel regulatory role 
of GnRH in the regulation of gonadotropins. However, we are not able to specify the 
function of each molecule in term of the regulation. Further work will be needed to 
identify the targets which mediate the effect to the gonadotropin. Moreover, we found 
crucial factors, which are involved in regulating calcium concentration, CaM-binding and 
CaM downstream signaling, were differentially regulated by GnRH pulse frequency. 
These findings further support the previous hypothesis that Ca
2+ 
signaling is crucial in 
decoding the GnRH frequency. The proposed functional roles of these potential 
regulators, however, need to be validated. Our iTARQ study provided valuable clues and 
suggestions for understanding the multifunctional roles of GnRH in the regulation of 
gonadotropins and building the interactive GnRH signaling pathways. 
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Chapter 6. Alpha-actinin 4-nuclear 
translocation mediates 
gonadotropin-releasing hormone 
stimulation of follicle-stimulating 
hormone β-subunit protein 




In last chapter, by using the iTRAQ-based proteomic profiling, we identified a number of 




signaling has been suggested to be 
involved in decoding the GnRH frequency driven by the intermittent changes in Ca
2+
 
concentration (Haisenleder, Yasin et al. 1997). So we expect that these regulated proteins 
may function differentially on Lhβ and Fshβ genes. One of them is actinin 4 (ACTN4). It 
carries a C-terminal calmodulin (CaM)-like domain, which has the potential to exert a 
similar function as CaM protein, the downstream effector of GnRH-induced Ca
2+ 
signaling, on the gonadotropin gene. To validate the function of ACTN4, we carried out 
the following study.  
Our study proved that ACTN4 is up-regulated in the nucleus of LβT2 cells induced by 
GnRH. Functional studies showed that ACTN4 may be a potential positive regulator of 
Fshβ gene transcription, likely through its C-terminal CaM-like domain.  
6.2 Results  
6.2.1 GnRH induces nuclear translocation of ACTN4 
ACTN4 was one of the proteins identified by the iTRAQ experiment, which showed 
significant abundance change upon 30 min GnRH-treatment. To confirm the up-
regulation of ACTN4 in the nucleus of GnRH-treated LβT2 cells, we examined the 
protein levels of ACTN4 in nucleus and cytoplasm by western blot analysis (Figure 6.1). 
The result demonstrates that GnRH stimulation increased the protein level of nuclear 
ACTN4 in both biological replicates (1.69±0.21-fold and 1.82±0.07-fold, respectively), 
which was consistent with our iTRAQ result.  
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Immunofluorescence confocal microscope study was performed to detect the subcellular 
distribution of endogenous ACTN4 in LβT2 cells after GnRH induction. In the mock-
treated cells, ACTN4 was predominantly accumulated as a circle surrounding the inner 
layer of plasma membrane. This is consistent with its role as a cytoskeleton protein. After 
GnRH treatment significant amount of ACTN4 was redistributed to nucleus as indicated 
in Figure 6.2 (a). Quantitation data showed that nuclear ACTN4 level increased by 
1.93±0.25 fold, confirming nuclear translocation of ACTN4 induced by GnRH (Figure 






Figure 6.1 Western blot validation of iTRAQ experiment. 
LβT2 cells from each of the two biological replicates were treated with 100 nM GnRH or 
mock. The nuclear (N) and cytoplasmic (C) fractions were separated as indicated in 
Materials and Methods. (a) The expression level of ACTN4 in each fraction was 
measured by western blot. NPM and GAPDH were the loading controls for nuclear and 
cytoplasm fractions, respectively. Representative blot was shown. (b) Quantification of 
nuclear ACTN4 was performed from three independent experiments (NPM was set as the 
control for normalization of nuclear protein) and the mean fold change over control 





Figure 6.2 Immunofluorescence analysis for intracellular distribution of ACTN4 
after GnRH-induction in LβT2 cells. 
(a) Redistribution of ACTN4 after GnRH treatment is indicated by the white arrows. The 
zoom-in images of single cells (marked by the white squares) from both mock-treated 
and GnRH-treated groups were shown at the right side of the panels. LβT2 cells were 
seeded on pre-coated coverslips and serum-starved for 12 hrs, and were exposed to 100 
nM GnRH or mock. Cells were fixed and then stained for ACTN4 (red) and nuclei with 
DAPI (blue). Scale bar=10 µm. (b) Quantification of confocal images. Results were 




ACTN4 is originally recognized as an actin-binding protein and predominantly localized 
at stress fibers, microfilament bundles, and sites of cell contact or adhesion, engaged in 
organization of actin cytoskeleton and regulation of cell motility (Honda, Yamada et al. 
1998). The translocation of ACTN4 from adhension site to nucleus through actin fibers 
upon hormonal stimulation is an efficient signaling pathway. Besides, the translocation of 
ACTN4 may result in the actin reorganization and cause the change of the cell 
morphology and activate the gene transcription. It was only until recently that the nuclear 
functions of ACTN4, as a transcription factor, started to be unveiled (Poch, Al-Kassim et 
al. 2004; Chakraborty, Reineke et al. 2006; Babakov, Petukhova et al. 2008; Khotin, 
Turoverova et al. 2010; Khurana, Chakraborty et al. 2011). 
6.2.2 Effects of ACTN4 on the transcription of mouse gonadotropin β-subunit 
genes and GnRHR gene 
As we found that ACTN4 nuclear translocation is increased upon GnRH treatment, we 
speculated that ACTN4 may also play a role in regulating transcription of gonadotropins. 
To test this hypothesis, the effects of overexpression and knock-down of ACTN4 were 
studied. Figure 6.3 is the western blot confirmation showing the effective up-regulation 
(7-fold) of ACTN4 by ACTN4 OE and down-regulation (4-fold) by siACTN42032. Since 
the knock-down efficiency of siACTN4976 was not as significant as that of 
siACTN42032, we only used siACTN42032 for the following experiments. We examined 
the effect of ACTN4 on the transcription of three of the tertiary gonadotrope signature 
genes (Salisbury, Binder et al. 2008): Fshβ, Gnrhr and Lhβ. RT-PCR result demonstrated 
that transient transfection of ACTN4 OE into LβT2 cells markedly promoted mFshβ 
mRNA level, while did not affect transcript levels of mLhβ and mGnrhr (Figure 6.4). The 
effect on mFshβ mRNA was further verified by quantitative real-time PCR (Figure 6.5). 
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ACTN4 OE increased the mRNA level of mFshβ gene to 1.46±0.13 fold (P<0.05), while 
siACTN42032 reduced mRNA level of mFshβ gene to 0.69±0.17 fold (P=0.07). The 
effect of siACTN42032 on the transcript level of mFshβ gene, though not statistically 
significant, showed opposite trend to the effect by ACTN4 OE. These findings indicate 
that ACTN4 positively regulates the transcription of mFshβ gene.  
 
 
Figure 6.3 Confirmation of the ACTN4 OE and knocking-down constructs by 
western blot. 
The expression level of ACTN4 OE (a) and knocking down (b) were assessed by western 






Figure 6.4 RT-PCR of ACTN4 effects on mFshβ, mGnrhr and mLhβ genes. 
pXJ40-FLAG-ACTN4 was transfected into LβT2 cells, total RNA was extracted. mFshβ, 
mGnrhr and mLhβ mRNA levels were measured by RT-PCR using 60S RP as an internal 
control, and levels are showed as fold change over those in pXJ40-FLAG transfected 
LβT2 cells. Values are mean±SEM of three independent experiments. t test comparing 






Figure 6.5 Quantitative real-time PCR of mFshβ gene. 
The experiment was performed using primers spanning an intron/exon border of the 
mFshβ gene.  Changes in cycle threshold values were normalized to those of 60S RP and 
compared to the levels in the cells transfected with control plasmids. Values are 
mean±SEM of three independent experiments. *P<0.05. 
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6.2.3 ACTN4 regulates mFshβ promoter 
Since the amount of ACTN4 in nucleus increases after GnRH treatment, we speculated 
that ACTN4 may exert its regulatory roles on the mFshβ promoter. Hence, we performed 
luciferase promoter assays to assess the effect of ACTN4 on mFshβ promoter activity. As 
shown in Figure 6.6, transient transfection of ACTN4 OE dramatically increased mFshβ 
promoter activity by 1.86±0.06 fold (P<0.001), while siACTN42032 repressed this 
promoter activity to 0.59±0.04 fold (P<0.001). Collectively, our data suggest that ACTN4 
is a positive regulator of mFshβ gene transcription, and likely has functional impact on 
mFshβ promoter. 
 
Figure 6.6 Effects of ACTN4 on mFshβ promoter. 
mFshβ promoter-firefly luciferase constructs were transiently transfected into LβT2 cells 
together with ACTN4 OE/empty vector or siACTN4/shGFP.  Firefly luciferase values 
were normalized to those of Renilla luciferase, and were shown as fold changes over 
levels in vector-transfected LβT2 cells. Values are mean±SEM of two independent 
experiments, each performed in four replicates. ***P<0.001. 
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6.2.4 ACTN4-induced transcriptional activation of mFshβ requires the CaM-like 
domain 
After verifying the effect of ACTN4 on the transcription of mFshβ gene, we further 
investigated which domain of ACTN4 plays a role in the transcriptional regulation. 
ACTN4 contains an N-terminal actin-binding domain, a central four spectrin-repeat 
domain, two EF-hand Ca
2+
-binding domains and a C-terminal CaM-like domain. 
Previous studies have found that the CaM-like domain of ACTN4 can antagonize histone 
deacetylase 7 (HDAC7) and consequently potentiate myocyte enhancer factor-2 (MEF2) 
transcription activity (Chakraborty, Reineke et al. 2006). Since MEF2 family member 
MEF2A and MEF2D are transcription factors bound to mFshβ promoter in αT3-1 cells 
(Lim, Luo et al. 2007), we anticipated that ACTN4 may also regulate transcription of 
mFshβ gene through its CaM-like domain. To test this hypothesis, the full-length ACTN4 
and its truncated mutant ΔCaM-ACTN4, without the CaM-like domain, were transiently 
transfected into LβT2 cells. The protein expression of each construct was analyzed by 
western blot (Figure 6.7 (a)). The effects of these proteins on the mRNA level of mFshβ 
gene were assessed by real-time PCR. The result demonstrates that ACTN4 OE promotes 
mRNA level of mFshβ gene to nearly 1.5 fold; however ΔCaM-ACTN4 has no detectable 
effect (Figure 6.7 (b)).  
Furthermore, luciferase assay was performed to evaluate the effect of ΔCaM-ACTN4 on 
the mFshβ promoter activity (Figure 6.7 (c)). The result shows similar trends as that of 
real-time PCR. Compared to the control, ACTN4 significantly increased mFshβ promoter 
activity for ~2 fold, while this function was almost abolished after deleting the CaM-like 
domain. Our findings suggest that the C-terminal CaM-like domain of ACTN4 might be 








Figure 6.7 ACTN4 induced transcription activation of mFshβ requires its CaM-like 
domain. 
(a) pXJ40-FLAG, ACTN4-FLAG and ΔCaM ACTN4-FLAG were transiently transfected 
into LβT2 cells. The expression of full length and truncated ACTN4 was detected by 
western blot with actin as loading control. (b) Real-time PCR of regulation of ACTN4 on 
the Fshβ gene. Total RNAs were extracted from LβT2 cells transfected with above 
plasmids. Quantitative real-time PCR was performed as described in Figure 6.5. (c) 
Luciferase assay of ACTN4 on mFshβ promoter. mFshβ promoter-luciferase constructs 
were co-transfected with either ACTN4-FLAG, ΔCaM ACTN4-FLAG or pXJ40-FLAG. 




Here we propose three possible roles of ACTN4 in GnRH-mediated transcriptional 
activation. Firstly, ACTN4 may promote the transcription of mFshβ through antagonizing 
HDACs from its promoter.  It has been reported that the ACTN4 and MEF2 binding sites 
on HDAC7 are largely overlapped. Furthermore, the CaM-like domain of ACTN4 is 
critical for its interaction with HDAC7. Because of these,  ACTN4, through its CaM-like 
domain, can compete with MEF2 for binding to HDAC7 thus potentiate MEF2 
transcription activity (Chakraborty, Reineke et al. 2006).  MEF2 is a known transcription 
factor bound to Fshβ promoter in αT3-1 cells (Lim, Luo et al. 2007), the released 
inhibition of MEF2 through dissociation with HDAC7 may therefore promote the 
transcription of Fshβ gene. Besides, ACTN4 may also regulate the direct inhibition of 
mFshβ promoter through releasing the HDACs from binding to the promoter. It has also 
been reported that GnRH facilitates the expression of mFshβ gene in αT3-1 cells through 
activating Ca
2+
/CaMKI and phosphorylating the HDACs (Lim, Luo et al. 2007). The 
phosphorylated HDACs dissociate from mFshβ promoter, thus the HDAC-mediated 
repression of mFshβ gene is released. This finding indicated that GnRH stimulation may 
trigger the Ca
2+
 signaling pathway as well. Thus, It is possible that ACTN4 is involved in 
regulating the transcription of mFshβ gene through GnRH-induced activation of Ca2+ 
signaling pathway, causing HDAC phosphorylation and relief of gene repression. 
Secondly, it is also possible that ACTN4 may stabilize chromatin remodeling complexes 
to activate mFshβ transcription. In the study of human cytochrome P450, family 1, 
subfamily A, polypeptide 1 (CYP1A1), association of ACTN4/ NF-Y has been identified 
and the role of ACTN4 has been proposed in assisting NF-Y to recruit chromatin 
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remodeling complexes or directing ACTN4/NF-Y associated gene into active 
transcription (Poch, Al-Kassim et al. 2004). Given that murine Fshβ promoter also 
contains a half AP-1/NF-Y binding site (Jacobs, Coss et al. 2003), and this site is required 
for the maximal induction of GnRH in LβT2 cells (Coss, Jacobs et al. 2004), we 
speculate that ACTN4 may help to stabilize chromatin remodeling complexes or 
orchestrate target genes to facilitate the transcription activation induced by GnRH. 
Thirdly, ACTN4 may link Ca
2+
 signaling and MAPK signaling during the GnRH-
mediated signal transduction pathways. It is known that the MAPK pathway is important 
for GnRH signaling in the regulation of synthesis of gonadotropins. Previous study on 
CaM in αT3-1 cells suggested that it may act as a Ca2+ sensor, which induces Ca2+ flux 
and consequently leads to extracellular regulated kinase (ERK) activation within the 
GnRH signaling (Roberson, Bliss et al. 2005). It is evident that ERK is a crucial 
intermediate to transduce the signal from GnRH to Fshβ. Inhibition of ERK decreased 
GnRH-induced mFshβ promoter activity in LβT2 cells (Coss, Jacobs et al. 2004) and 
attenuated GnRH-stimulated mRNA level as well as FSH release in male rat primary 
pituitary cultures (Haisenleder, Cox et al. 1998). As ACTN4 harbors the CAM-like 
domain, it may also mediate the activation of ERK through GnRH-induced Ca
2+
 
signaling. In this study, we demonstrate that ACTN4 may play an essential role on the 
mFshβ promoter through its CaM-like domain. Therefore, it is plausible that ACTN4 also 
provides a link between Ca
2+
 signaling and MAPK signaling during the GnRH-mediated 
signal transduction pathways (Naor, Benard et al. 2000). The above mentioned 
hypothesis was summarized in Figure 6.8. Further experiments will be required to verify 
this complex signaling process. 
176 
To summarize, we have demonstrated that the nuclear translocation of ACTN4 is 
involved in the regulation of mFshβ gene transcription by GnRH, and its CaM-like 
domain is required for this function. Our findings suggest that GnRH-induced ACTN4 
nuclear translocation may facilitate the transcriptional activation of mFshβ gene, possibly 
through mediating the crosstalk of Ca
2+ 
signaling with the MAPK pathways. 
 
 
Figure 6.8 Proposed functional roles of ACTN4 in the regulation of FSHβ gene 
transcription.  
ACTN4 may function through regulating CaMKs and consequently dephosphorylates and 
releases HDACs from binding on the FSHβ promoter; ACTN4 may also binding with 
HDACs and subsequently prevent the HDACs binding to the MEF, as a result to induce 
FSHβ gene transcription; ACTN4 can bind to NFY and recruit other factors to induce 
FSHβ gene transcription; ACTN4 may also mediate the crosstalk between Ca2+ signaling 
and MAPK pathway, possibly through ERK. 
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7.1 Conclusion of the Study  
GnRH is the first key hormone of reproduction. GnRH analogs are extensively used in in 
vitro fertilization, and treatment of sex hormone-dependent cancers. An understanding of 
the GnRH signaling mechanisms is crucial for establishing interactive signaling map, 
pointing to targets for new drugs. However, during the past 10 years, the majority of the 
study was focused on GnRH-induced MAPK cascades and the MAPK mediated 
transcriptional regulation of gonadotropins. Although the knowledge of these fields are 
quite solid and specified, in terms of new drug development, however, the knowledge is 
too limitated. Thus there is a need to discover new pathways and new regulatory 
mechanisms initiated by GnRH. As such we performed high-throughput proteomic 
studies in LβT2 gonadotrope cell line.  
As described in chapter 4, we began with cICAT proteomic profiling, where comparison 
between whole-cell proteome from 4 h mock-treated and GnRH-treated LβT2 cell lines 
was performed allowing an identification of differentially regulated low abundant 
signaling proteins. We found several significantly regulated proteins were involved in 
PTMs, suggesting the involvement of new GnRH-regulatory mechanisms. Furthermore, 
we found a few potential mediators which may mediate GnRH response to Wnt/β-catenin 
signaling. Based on our finding we proposed a model showing the crosstalk between 
GnRH signaling and Wnt signaling. We proposed that β-catenin may be stabilized by two 
distinct strategies. One is through β-catenin phosphorylation-dependent mechanism, 
which may be mediated by either GSK-3β Ser 9 dependent-mechanism, or GSK-3β Ser 
9-independent mechanism or both. The other is through β-catenin phosphorylation-
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independent mechanism, which is mediated by Cacybp-containing E3 ubiquitin complex, 
and this pathway is possible to connect Wnt signaling with MAPK cascades.  
Although our cICAT proteomic profiling study allows the identification of several 
signaling molecules, the overall number of the proteins identified by ICAT is relatively 
small thus not sufficient to interpret the GnRH signaling from a comprehensive 
perspective. So in Chapter 5 we used an alternative proteomic method, iTRAQ-based 
proteomics experiment, to perform the nuclear proteomic comparative profiling in mock-
treated and GnRH-treated LβT2 cells.  Rather than just a repetitive study, our iTRAQ 
study changed the GnRH treatment from continuous treatment to pulse treatment, which 
better represent the physiological condition (Lawson, Tsutsumi et al. 2007).  In iTRAQ 
study, we identified a number of differentially regulated proteins with novel functional 
roles such as mRNA processing, translation, and chromosome organization, suggesting 
multifunctional roles of GnRH in the regulation of gonadotropins.  Furthermore, we 
identified several potential Ca
2+ 
signaling regulators, which are involved in regulating 
calcium concentration, CaM-binding and CaM downstream signaling, were differentially 
regulated by GnRH pulse frequency. These findings provide more evidence suggesting 
the crucial role of Ca
2+ 
signaling in decoding the GnRH pulse frequency.  
Finally we validated one of the iTRAQ identified proteins, ACTN4, which was found to 
be involved in Ca
2+ 
signaling. We proved that ACTN4 is a positive regulator of FSHβ 
gene transcription, and the CaM-like domain is required for this function. The results also 
suggested that ACTN4-induced transcriptional activation of mFshβ gene, possibly 
through mediating the crosstalk of Ca
2+ 
signaling with the MAPK pathways.  
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In summary, our study is the first comprehensive proteomic study which was performed 
in gonadotrope cell line to explore the GnRH signaling. Our finding identified novel 
functional roles of GnRH and novel pathways mediating GnRH response to 
gonadotropins (Figure 7.1). Our findings may provide valuable clues and suggestions for 
future researches to continue exploring the interactive GnRH pathway networking, as 
well as identifying potential drug targets for the therapy of reproductive aberrance and 




Figure 7.1 Summary of the identification of novel functional roles of GnRH and 
novel pathways mediating GnRH stimulation of gonadotropin production. 
In this proteomic study, we identified a number of differentially regulated proteins with 
novel functional roles such as mRNA processing, translation, and chromosome 
organization, suggesting multifunctional roles of GnRH in the regulation of 
gonadotropins. Moreover, the novel signaling pathways mediating transcription of 
gonadotropins, include Wnt and Ca2+ signaling, have been revealed. For Wnt signaling, 
the mechanisms of β-catenin phosphorylation-dependent and phosphorylation-
independent pathways were proposed (Figure 4.9). For Ca2+ signaling, a number of 
CAM binding proteins were revealed and the downstreams CAMKs pathway and 
calcineurin pathway were discussed ( 
Figure 5.11).   
 
7.2 Future directions 
Based on the new findings obtained toward GnRH signaling and gonadotropins 
regulation, we suggest focusing the future works on the following areas: 
 Wnt signaling  
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We have identified several candidates which may mediate GnRH response through Wnt 
signaling, further work will be done to verify their functions based on the model 
proposed in Fig. 4.9. The mechanism of β-catenin stabilization can be investigated as 
shown in Figure 7.2. 
 
Figure 7.2 Investigation of GnRH-induced β-catenin stabilization mechanism. 
 Ca2+ signaling 
We have identified crucial factors induced by GnRH, which are involved in regulating 
calcium concentration, CaM-binding and CaM downstream signaling. Further work will 
be done to verify their functions based on the model proposed in Fig 5.10. The 
involvement of the candidates in  Ca
2+ 





Figure 7.3 Investigation of the involvement of Ca
2+
 concentration regulators, CAM-
binding proteins in the regulation of gonadotropins.  
 Chromosome remodeling 
We identified several chromatin regulators. They are possibly involved in regulating two 
chromosome co-repressor complexes, which recruit HDACs to the chromosome and 
inhibit the transcription (Figure 5.10). Further work will be performed to validate the 
involvement of these factors (Figure 7.4) 
 
Figure 7.4 Investigation of the proteins involved in chromosome organization. 
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 Promoter pull-down based proteomic study 
Several transcription factors have putative binding site (s) on LHβ and FSHβ promoters 
(Halvorson, Ito et al. 1998; Dorn, Ou et al. 1999; Jacobs, Coss et al. 2003). As these 
transcription factors are able to recruit other coactivators to the corresponding promoters, 
we designed a promoter pull-down based proteomic study (Figure 7.5). We expect that 
coactivators for each specific promoter can be identified using this method. Compared to 
our current proteomic profiling, this new approach may provide more specific findings of 
how GnRH response is mediated to each gonadotropin promoter. We did a preliminary 
test to check the applicability of the promoter pull-down experiment by using LHβ intact 
and mutant promoters. As shown in Figure 7.6, this method is efficient and specific thus 








Figure 7.6 Sf-1 promoter pull-down experiment.  
5’bio-mutant promoter without Sf-1 binding site fails to pull down Sf-1 (Lane 2), while 
5’bio-intact promoter with two Sf-1 binding sites pulls down Sf-1 successfully (Lane 3). 
Combining the 5’bio-intact promoter with the competitor, nobio-intact promoter shows 
thatincreasing amount of competitor results in reduced amount of Sf-1 pulled down (Lane 
4, 5). The nobio-mutant promoter can’t compete with 5’bio-intact promoter, so there is no 
difference of Sf-1 pull down between Lane 6 and Lane 2. The input Sf-1 is nearly 
undetectable (Lane1), while the pull-down of Sf-1 is obvious (Lane 3 and 6), indicating 
high efficiency and specificity of this experiment.  
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 Pulse frequency operation model  
In our study we tried to use 30 min and 4 h GnRH treatments to mimic the high and 
low GnRH frequencies. We did observe several proteins were differentially regulated 
by 30 min and 4 h GnRH-treatments, which may help to explain the previous 
observation that GnRH pulse frequency differentially regulate the expression of LHβ 
and FSHβ genes (Bedecarrats and Kaiser 2003). However, compared to the 
continuous GnRH-pulsatile secretion in the physiological condition, our experiment 
can only mimic single pulse. Lawson’s group has developed a pulse generating 
system, named LβT2 perifused system, which has only been applied to the genomic 
study (Bedecarrats and Kaiser 2003; Lawson, Tsutsumi et al. 2007). Thus we may 
borrow their idea and apply the pulse generator to our future proteomic study. 
 From in vitro study to in vivo study 
We have mentioned in Chapter 1 that there were some conflicting results towards 
GnRH regulation of gonadotropins. These conflicting results were suggested due to 
different cell type, promoters, species, and cell culture conditions (Naor 2009). 
Although work published in the past few years have clarified some of these 
ambiguities, more work is required to elucidate the molecules that mediate the 
hormonal activation of gonadotropins in different species and under various 
physiological settings and not just those that can bind and activate transcription in 
vitro. This will inevitably require greater use of animal models. 
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